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Zusammenfassung 
Hintergrund und Zielsetzung: In allen Gesundheitssystemen spielen Medizin-
produkte (MPs) eine wichtige Rolle. Im letzten Jahrzehnt hat sich die öffent-
liche Aufmerksamkeit verstärkt auf unsichere und unwirksame Hochrisiko-
MPs gerichtet. Die Folge ist eine zunehmende öffentliche Diskussion darüber, 
dass der Zulassungsprozess für Medizinprodukte kein Garant für qualitativ 
hochwertige und sichere Gesundheitsversorgung mit MPs ist.  
Dieser Forschungsbericht liefert zu einem eine Übersicht zu den Zulassungs-
verfahren insb. für MPs mit hohen Risiken in vier ausgewählten Regionen 
(USA, Kanada, Australien, Europa). Zum anderen werden die Anforderungen 
an klinische Evidenz und die öffentlich zugänglichen Informationen zum 
Zeitpunkt der Zulassung und zum Zeitpunkt der Bewertung vor einer Refun-
dierung für sieben ausgewählte Hochrisiko-MPs analysiert. 
Methode: Eine Literatursuche in PubMed, ergänzt durch Internet-Recher-
chen ist die Grundlage für die Übersicht über die vier Zulassungssysteme und 
deren Anforderungen an klinische Evidenz, insb. für Hochrisikoprodukte. 
Exemplarisch wurden sieben Medizinprodukte aus unterschiedlichen medi-
zinischen Fachgebieten und Indikationsbereichen ausgewählt. Öffentlich zu-
gängliche Informationen (offizielle Berichte der Zulassungsbehörden, Infor-
mationen der Hersteller, Ergebnisse der Literaturrecherche und Auswertung 
des Registers für klinische Studien) zum Zeitpunkt der Zulassung und zum 
Zeitpunkt der Refundierungsbewertung wurden gesucht und ausgewertet. 
Zuletzt wurde der „Level of Evidenz“ in einer Evidenzpyramide zusammen-
gefasst.  
Ergebnisse: Alle sieben ausgewählten Medizinprodukte haben in Europa eine 
Marktzulassung durch einen „Notified Body” (Benannte Stelle), nur vier in 
Australien durch die „TGA/Therapeutic Goods Administration“, je eines durch 
die US-Amerikanische „FDA/Food and Drug Administration“ und die Ka-
nadische „TPD/Therapeutics Products Directorate“. Im Vergleich ist die An-
zahl in Europa hoch, zumal vier weitere Medizinprodukte auch durch die 
FDA geprüft, aber zurückgewiesen oder nicht für eine breite Anwendung 
zugelassen wurden. 
In nahezu allen Beispielen wurde die Europäische Zulassung zwischen zwei 
und fünf Jahren vor der Antragstellung/Zulassung anderswo gewährt. Trotz-
dem die klinische Evidenz, die zur Europäischen Zulassung führte, nicht 
bekannt ist (aufgrund des dezentralen und intransparenten Zulassungssys-
tems), ist diese – naturgemäß, weil früher – auf einem niedrigeren Evidenz-
niveau. Im Gegensatz dazu wird keines der sieben Medizinprodukte – auf-
grund des Mangels an Nachweisen von PatientInnennutzen – von einem HTA-
Institut für eine generelle Refundierung empfohlen. Wenn doch, so lediglich 
im Forschungskontext. 
Diskussion und Fazit: Die Ergebnisse unterstützen die Forderung einer Ver-
änderung des Europäischen Medizinprodukte-Zulassungssystems, insb. für 
Hochrisikoprodukte zugunsten eines transparenten und evidenz-basierten 
Vorgehens. Bedingte Erstattung oder Erstattung unter der Bedingung von 
Generierung zusätzlicher Daten werden als Steuerungsinstrumente eingesetzt, 
um die große Kluft zwischen Medizinprodukten mit unsicherer Datenlage 
und den Erfordernissen für Refundierungsentscheidungen zu schließen. 
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Executive summary 
Background and objectives: Medical devices play an important role in health-
care systems. In the last decade, public awareness has been raised because of 
unsafe and ineffective high-risk devices entering markets. Consequently, ev-
idence requirements for the market authorization process of medical devices 
may not be enough to ensure high-quality and safe provision of care.  
This research first explores the authorization systems for high-risk medical 
devices in four selected regions (USA, Canada, Australia and Europe). Sec-
ondly, it analyzes the clinical evidence accessible at time of market approval 
and decision support (HTA) for reimbursement for seven selected high-risk 
medical devices.  
Methods: A literature review in PubMed, complimented with a worldwide 
web search, was conducted about the authorization systems and their evidence 
requirements, esp. for high-risk devices, in the four selected regions. After a 
selection of seven high-risk devices across a broad range of medical special-
ties and indications information about clinical evidence accessible at time of 
authorization, evidence used for authorization and for pre-reimbursement as-
sessments was searched and extracted from official reports, manufacturers, a 
literature search for each device in PubMed, and a search in a clinical trial 
registry. All accessible evidence was summarized in an evidence pyramid to 
show the levels of available evidence at time of approval and at time of pre-
reimbursement assessment. 
Results: All seven medical devices have been approved in the European Union 
through an appointed Notified Body, only four by the Australian TGA/Ther-
apeutic Goods Administration, one each by the US-American FDA/Food and 
Drug Administration and by the Canadian TPD/Therapeutics Products Di-
rectorate. In comparison to the other three regulatory systems, the number 
of approved devices in Europe is high, esp. if additionally taken into consid-
eration that four further devices were also assessed by the FDA, but either 
rejected or not approved for general use. 
In almost all of the seven analyzed examples, the premarket approval in Eu-
rope was granted two to five years before authorization in other systems. The 
evidence used for CE marking is not known due to the highly decentralized 
authorization system and the lack of transparency. Since authorization in 
Europe is earlier, the clinical evidence is naturally less mature. In contrast, 
none of the seven medical devices has been recommended for reimbursement 
yet. The pre-reimbursement assessments most often state that current evi-
dence is not enough to ensure patient benefit and safety. Some devices are 
recommended for “research only.” 
Discussion and conclusion: The results support a change in the European 
authorization system towards a transparent and evidence-based regulation 
process. Conditional coverage or coverage under evidence development is ap-
plied as instrument to close the gap between immature data and reimburse-
ment requirements. 
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1 Introduction 
Healthcare systems all around the world highly depend on the usage of med-
ical devices in the diagnosis, prevention and treatment of diseases [1]. It has 
been recognized that by means of a significant contribution of medical device 
technology, patients nowadays enjoy longer lives of higher quality. Especial-
ly for treatments in the cardiovascular, orthopedic and oncological fields, 
new devices are offering better alternatives to existing care standards [2]. In 
general, it can be observed that the advances in medical technologies have en-
hanced patient health outcomes [3]. As a result, a common objective of health-
care systems is to ensure and improve the access, quality and usage of medi-
cal devices [4].  
Medical devices can range from the simplest daily life supports such as stick-
ing plasters, pregnancy tests and contact lenses to the most sophisticated and 
advanced actively implantable devices like pacemakers and hip replacements 
[5]. In the European Union Medical Devices Directive, medical devices are 
described as “Any instrument, apparatus, appliance, software, material or 
other article, whether used alone or in combination, including the software 
intended by its manufacturer to be used specifically for diagnostic and/or 
therapeutic purposes and necessary for its proper application, intended by the 
manufacturer to be used for human beings” [6]. International definitions of 
medical devices may carry some variations, creating even more room for di-
versity and complexity in this sector [7].  
This diversity poses major challenges to healthcare systems, especially relat-
ing to regulation and financial access to medical devices [8]. The primary aim 
of regulation is the safe, high-quality and effective patient access to medical 
devices and the market restriction for those products that are ineffective and 
unsafe. Problems related to medical devices, such as unsafe and risky char-
acteristics, can have serious health consequences for the end-user.  
To be able to ensure this primary aim through regulation, medical devices 
have to undergo several assessment and evaluation procedures in their usual 
life-cycle [9]. First, an authorization process, in which an in-depth assess-
ment of the device and its characteristics for market entry is performed. Sec-
ondly, the reimbursement evaluation of the responsible national health au-
thorities in which the “value” based on the effectiveness of the device is identi-
fied.  
 
 
1.1 Background: Problem statement 
In comparison to the pharmaceutical approval and reimbursement process, 
less attention has been paid to the approval and reimbursement process for 
medical devices. As a clear international history of regulating the processes 
of pharmaceuticals exists, no clear international medical device regulations 
have been set [4]. This can be explained by the high diversity and complexity 
of products in the medical device sector. Currently, many healthcare systems 
are struggling with the implementation of appropriate medical device evalu-
ation practices [10].  
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Two of the most important world markets for medical devices, the United 
States of America and the European Union, have gone through a remarkable 
medical device regulation history. Nowadays they approach the regulation of 
medical devices in a vastly different manner.  
 In the United States of America, device regulation began as early as 
1938, and the regulatory structure reflected the relative simplicity of 
the medical devices being marketed at that time. In 1976, this regula-
tory structure was no longer adequate to deal with the high variation 
of medical devices and the increasing sophistication of the newly de-
veloped devices. The American Congress reacted to the sporadic pub-
lic health incidences associated to low patient safety through unsafe 
and risky device usage and established the Medical Device Amend-
ments of 1976 [11]. The law has been updated twice since then. 
 In the European Union, the medical device regulatory system is quite 
young, approximately 25 years behind the regulation from the United 
States of America. The European regulatory system for medical devices 
is embedded in the single market policy (EU Article 100/100a for the 
European single market) and three device-specific core directives. First, 
the council directive on active implantable medical devices (AIMD, 
90/385/EEC), agreed upon in June 1990 [12]. This directive was the 
first to be in force in European Member States from the 1st of January 
1993. Secondly, the council directive on medical devices (MDD, 93/ 
42/EEC) that has been effective in all Member States from the 1st of 
January 1995 [6]. Thirdly, the European Parliament and the council 
directive of in vitro diagnostic devices (IVDD, 98/79/EC) [13]. This di-
rective went in force on the 8th of December 1998 after a revision and 
consultation time of almost 8 years and amended sections within the 
AIMD and the MDD. On September 24, 2013, a revision of the Euro-
pean Medical Device Directive was implemented. The main changes 
included in the new directive are a clearer scope for the EU regulation, 
a stronger assessment of the Notified Bodies and clearer responsibili-
ties, an extended EUDAMED database, updated classification rules 
and more coordination. The target for adoption is 2014.  
While innovation brings a great variety to the medical device sector on the 
one hand, it brings challenges regarding evidence standards for the authori-
zation and reimbursement processes on the other hand [14]. Yet, regulatory 
processes such as authorization and reimbursement of medical devices re-
quire certain evidence standards to base decisions on. It has to be recognized 
that the study evidence on which a device approval decision is based certainly 
has to be of high quality. A gold standard for evidence that is set up in phar-
maceutical assessments would consist of randomized, double-blinded stud-
ies with adequate controls, sufficient duration, and a long follow-up on pre-
selected primary endpoints without bias [15]. Nonetheless, no adequate gold 
standards have been implemented in the medical device sector yet, and ethi-
cal drawbacks for randomized controlled trials may be present.  
Missing clear requirements for evidence to be submitted within the authori-
zation and reimbursement processes, healthcare systems experience difficul-
ties in their regulation of medical devices. In various regions, it can be ob-
served that device approval systems have become incapable of assuring safe-
ty, effectiveness and performance standards [16]. There is a clear need for the 
implementation of new approaches in the medical device sector.  
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1.2 Aim and objective 
This report aims to provide insight into the authorization process and its as-
sociated evidence requirements for high-risk medical devices in the USA, Eu-
rope, Australia and Canada. Further, this research aims at assessing the evi-
dence for seven selected high-risk medical devices upon time of authorization 
approval and reimbursement decisions.  
This research has two main objectives: 
 First, to explore and explain the authorization systems for medical de-
vices in four selected regions, namely the USA, Canada, Australia and 
Europe: The main characteristics of regulatory bodies, medical device 
classification approaches, authorization procedures and the associated 
evidence requirements for each of the regions are described. Differen-
ces and similarities of the four systems are summarized and compared.  
 Secondly, to investigate the evidence that is available for the seven 
high-risk medical devices at the time of authorization approval and 
reimbursement decision. All information is summarized and presented 
in an evidence pyramid.  
 
 
1.3 Scope of project and limitations 
The scope of this research is limited in a number of ways.  
 First, the research aims to only explore the evidence requirements for 
authorization and reimbursement for high-risk medical devices. This 
entails that only medical devices from the Class III device category 
will be included in the research [6].  
 The research focuses on the regulatory frameworks of the four selected 
regions: the USA, Europe, Australia and Canada. Information provid-
ed is therefore only applicable within in these selected regions. 
 Furthermore, the authorization process will only be examined within 
accredited regulatory bodies. Consequently, the FDA (USA), Notified 
Bodies (Europe), the TGA (Australia) and Health Canada (Canada) are 
included. Documents referring to the evidence used within an authori-
zation decision will only be used when issued by these regulatory bod-
ies.  
 Only information that has been publicly accessible can be included in 
this research. That means that the information collection is limited to 
open homepages of regulatory bodies, databases and published litera-
ture.  
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 Additionally, national institutes or authorities (many countries have 
more than one) that are relevant for the reimbursement decision will 
be chosen on the basis of available information about the devices in 
question. These institutes are by no means representative of all regu-
latory reimbursement bodies, but have been chosen to serve as exam-
ples. In Europe, the situation will be represented only by a selection 
of six countries and their relevant reimbursement authorities; there-
fore, generalizability to all European Member States is limited. 
 Moreover, the research is limited to the assessment of seven devices 
selected on the representation of all major indications that are depend-
ent on high-risk medical devices. It is understood that these devices 
can only serve as examples and that generalizability may be restricted.  
 
restricted selection of 
reimbursement agencies 
seven high-risk devices 
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2 Methods 
The data collection for this research is divided into three main parts: first, 
the search for information on the authorization; second, the reimbursement 
processes and their associated evidence requirements; third, the search for 
accessible information at the time of authorization approval and reimburse-
ment decision of the high-risk medical devices.  
 
 
2.1 Selection of regions 
This research focuses on four selected regions, namely the United States of 
America, Europe, Australia and Canada. The four regions represent the West-
ern industrialized world and can be considered as major impact countries for 
the medical device sector. Moreover, healthcare systems within these regions 
are highly dependent on medical devices. 
 
 
2.2 Selection of high-risk medical devices 
The high-risk medical devices included in this research had to meet some in-
clusion criteria: They were chosen out of a broad range of medical specialties 
and indications that depend on the use of devices. Further, only high-risk 
medical devices, the highest risk classification, were selected, since the most 
stringent evidence requirements for the authorization process and reimburse-
ment decisions are required in this class. Based on these criteria, seven high-
risk medical devices were chosen (Table 2.2-1).  
Table 2.2-1: Seven exemplary high-risk medical devices 
Medical Device  Manufacturer Medical Specialty 
Zephyr® Endobronchial Valve  PulmonX Pulmonology 
Paracor Ventricular Support System (PVSS) Paracor Medical Inc.  Cardiology 
Annular repair device Barricaid® Intrinsic Therapeutics, Inc. Orthopedics 
Rheofilter ER-4000 Asahi Kasei Medical Co.  Ophthalmology 
BSD-2000 Microwave Hyperthermia System  BSD Medical  Oncology 
Amplatzer™ PFO Occluder St. Jude Medical  Cardiology 
MitraClip® Abbott  Cardiology 
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2.3 Authorization 
The data collection for the authorization part is based on a literature search 
and on official reports from the relevant national regulatory bodies (except 
Notified Bodies, due to intransparency).  
The literature search first focused on the national authorization processes 
and their characteristics. The search was conducted in an academic database 
through PubMed, as well as in the worldwide web in an iterative way. All 
search outcomes were documented and underwent a selection process. Prede-
fined inclusion and exclusion criteria guided the literature selection process. 
All relevant steps are documented in a PRISMA-tree (See Appendix 1). The 
main inclusion and exclusion criteria for the data selection are presented in 
Table 2.3-1. All literature selected in the first screening underwent a second, 
more thorough examination.  
Keywords used during the search were High-risk medical device* AND method-
ology* AND “clinical evaluation”* AND class III devices* AND market authori-
zation* AND Europe* AND United States of America* AND Australia* AND 
Canada* AND TGA* AND Health Canada* AND FDA* AND evidence re-
quirements* AND guidance for medical devices* AND assessment methods* 
Table 2.3-1: Inclusion and exclusion criteria for the authorization data collection 
Inclusion criteria Exclusion criteria 
 In English or German language  
 Relevant for the four selected regions 
 Focus on evidence requirements  
 Comparison analysis of authorization 
processes  
 Publications about the selected s 
even devices  
 High-risk medical devices  
 Publications available from 2000  
until July 2013  
 Very broad general narrative descriptions  
 Publications about low-tech devices  
 Clinical trial summaries of specific medical devices (only 
inclusion with focus on one of the seven selected devices) 
 Publications about in-vitro diagnostics, medical device 
software, nanotechnology, off-label use, combination 
products and biotechnical engineering 
 Descriptions about export and import of medical devices  
 Supplement articles to already existing devices  
 
 
2.4 Reimbursement 
The data collection for the reimbursement section consisted of a literature 
search and of public reports from relevant reimbursement institutions.  
The literature search concentrated on the reimbursement practices and evi-
dence requirements in the four selected regions. The search was conducted 
in an academic database through PubMed, as well as in the worldwide web 
in an iterative way. All search outcomes were documented and underwent 
a selection process. Predefined inclusion and exclusion criteria guided the 
literature selection process within the systematic literature review. All rele-
vant steps are documented in a PRISMA-tree (See Appendix 2). The inclu-
sion and exclusion criteria are presented in Table 2.4-1.  
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Keywords used during the search were High-risk medical device* AND “clinical 
evaluation”* AND class III devices* AND reimbursement* AND Europe* AND 
The Netherlands* AND Germany* AND England* AND Austria* AND France* 
AND Belgium* AND United States of America* AND Australia* AND Canada* 
AND TGA* AND Health Canada* AND evidence requirements* AND guidance 
for medical devices* AND assessment methods* AND evaluation methods* AND 
HTA assessment* 
Table 2.4-1: Inclusion and exclusion criteria for the reimbursement data collection 
Inclusion criteria  Exclusion criteria  
 In English or German language 
 Relevant for the four selected 
regions 
 Focus on the national 
reimbursement practices  
 Publications available from 2000 
until October 2013  
 Very broad general narrative 
descriptions  
 Special reimbursement reports 
of pharmaceuticals or other 
technologies 
 Supplement articles to 
reimbursement decisions 
 
The second part of the data collection was based on public reports from re-
imbursement agencies or HTA institutes from the four selected regions. In-
formation about evidence requirements and assessment methods used for the 
reimbursement decision were searched for. All data available in German and 
English were included in this research.  
The reimbursement agencies or HTA institutes selected for this research are 
listed in Table 2.4-2.  
Table 2.4-2: Reimbursement agencies and HTA institutes 
United 
States of 
America 
 Centers for Medicare and Medicare Services (CMS) 
 Aetna 
 Blue Cross and Blue Shield (BSBC)  
 United Healthcare 
 Kaiser Permanente  
 Agency for Healthcare Research & Quality (AHRQ)  
Europe  The Netherlands – College voor zorverzekeringen (CVZ) 
 Germany – MDS, Federal Joint Committee (G-BA), Institute 
for Quality and Efficiency in Healthcare (IQWIG) 
 England – National Institute for Health and  
Care Excellence (NICE)  
 Austria – Ludwig Boltzmann Institute for HTA (LBI)  
Australia  Medical Services Advisory Committee (MSAC) 
Canada  Canadian Association of Healthcare Reimbursement (CAHR) 
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2.5 Accessible clincial evidence  
for seven high-risk medical devices 
A literature search on the seven exemplary medical devices was performed. 
An academic database (PubMed) was searched. The keywords used during the 
search were the product name of the seven selected devices and the associat-
ed indication.  
In addition, the regulatory bodies responsible for the authorization procedure 
in the four selected regions were contacted, and information about the evi-
dence used for the authorization decision of the seven medical devices was 
requested. The bodies that were contacted are the FDA in the United States 
of America, Health Canada in Canada and the TGA in Australia. A standard-
ized e-mail was sent to the relevant departments within the regulatory bodies.  
Furthermore, the manufacturers of the seven devices selected for this research 
were approached with the request to provide information about the evidence 
submitted to the regulatory bodies in the four regions during the authoriza-
tion process. A standardized e-mail was sent to the manufacturers.  
The clinical trial registry clinicaltrial.gov was scanned using the product name 
of the seven devices and the associated indication as keywords.  
Further, public reports from reimbursement agencies or HTA institutes from 
the four selected regions (Table 2.4-2) on the seven exemplary devices were 
searched for. Only the exemplary medical devices approved through the au-
thorization process in the regions were further assessed for reimbursement 
decisions. The reimbursement agencies were selected based on the existence 
of publicly available assessment reports in English or German. 
All gathered information was summarized in a comprehensive and systematic 
way, and is presented within a separate section for each of the seven medical 
devices.  
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2.6 Research questions 
The research project especially focuses on the evidence requirements used for 
the authorization process and the reimbursement decisions in the four select-
ed regions. The main, guiding research questions have been organized within 
the two main focus points: the authorization and reimbursement processes. 
Moreover, research questions focusing on the comparison of both processes 
and overlapping evidence requirements have been formulated: 
Authorization:  
 How do the premarket authorization processes for high-risk medical 
devices in the four selected regions work and what evidence is re-
quired?  
 What are the major similarities or differences of the authorization pro-
cesses for high-risk medical devices in the four selected regions?  
 What evidence is available for the seven selected high-risk medical 
devices? What is the scientific basis for the premarket authorization?  
Reimbursement:  
 How do the reimbursement processes for high-risk medical devices in 
the four selected regions work and what evidence is required?  
 What are the major similarities or differences of the reimbursement 
processes for high-risk medical devices in the four selected regions? 
 What evidence is available for the seven selected high-risk medical 
devices regarding the process for the reimbursement decision? 
Comparison:  
 Which policy improvements are proposed for the premarket authori-
zation and the reimbursement decision in the four selected regions? 
 How can the evidence requirements be more harmonized between the 
two processes of authorization and reimbursement? 
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3 Authorization 
The regulations for the authorization process of medical devices are multi-
faceted. Manufacturers seeking to place a new medical device on the market 
generally have to provide evidence about the characteristics of the device 
based on its potential risk. These risk-appropriate regulatory frameworks are 
of utmost importance for the regulation and control of the massive number 
of heterogeneous products in the medical device sector. One of the primary 
aims of these regulations is to ensure timely patient access to safe and effec-
tive technology [17].  
This chapter starts by introducing the current challenges within the authori-
zation of medical devices. Subsequently, four different authorization systems 
from the United States of America, Europe, Australia and Canada and the as-
sociated evidence requirements for high-risk medical devices are described. 
 
 
3.1 Challenges in the authorization 
process of high-risk medical devices 
According to the World Health Organization, 1.5 million different medical 
devices currently exist around the world [5]. The sector covers a wide range 
of products and is consequently struggling with the appropriate authoriza-
tion systems to regulate and control the device markets. This struggle has 
been clearly highlighted through the scandals of unsafe and dangerous de-
vices being marketed, especially in the European single market [18].  
Authorization systems have been criticized for lacking transparency in their 
processes and for not stating clear evidence requirements for the assessment 
of clinical and patient benefit [19]. In response to the on-going debate and 
criticism, the medical device sector has provided the public with the major 
challenges of effective regulation and control. 
 First, the evidence generation for medical devices is assumed to be 
more complex than for pharmaceuticals. In particular, to perform a 
randomized clinical trial with high-risk medical devices using place-
bos as comparators is (often) impossible due to ethical research stand-
ards [4]. Therefore, other study designs such as (retrospective or pro-
spective) case series are the only available evidence for the approval 
process.  
 Secondly, the medical devices sector is overwhelmed by small- to me-
dium-sized enterprises (SMEs) compared to the pharmaceutical sec-
tor, where only large, experienced enterprises are present. In general, 
SMEs neither have the resources nor the experience to perform large 
clinical trials for their products [20].  
 Thirdly, authorities are asked to handle a great amount of products 
varying in characteristic and performance. In comparison to the phar-
maceutical sector, the medical device sector and its regulatory frame-
works are approximately 25 years younger [21].  
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3.2 USA: FDA/Food and Drug Administration 
The following section presents the authorization system in the United States 
of America. First, the regulatory body responsible for the authorization is in-
troduced. Secondly, the current classification system for medical devices is 
presented and the authorization is explained in more detail. Finally, evidence 
requirements requested by the FDA are summarized.  
 
3.2.1 Regulatory body 
The authorization process for medical devices in the United States of Amer-
ica is primarily the responsibility of the Food and Drug Administration 
(FDA). The FDA is a centralized body that is not only responsible for medi-
cal devices, but in general for the protection of the public health of American 
citizens [22]. That includes the supervision and assessment of all products as-
sociated with human health. In the medical device sector, the FDA regulates 
the manufacturer’s application for market entry of a new device. A manufac-
turer must receive FDA permission before its device can be legally marketed 
in the United States. A subdivision of the FDA, the Center for Devices and 
Radiological Health (CDRH), is the main reviewing body for submitted pre-
market applications [23].  
 
3.2.2 Classification 
In the American system, every medical device has to be classified into its ap-
propriate risk class before submission of any evidence to the FDA. The manu-
facturer itself has to identify the risk class of the device based on the poten-
tial risk the device carries for its user. In general, there are three different risk 
classes a device could be classified to. Device classification determines the 
kind of application a manufacturer must submit to the FDA [24].  
 Class I is the low-risk class of devices. These devices present minimal 
potential harm to the user and their design is often less complex than 
designs from higher risk class devices. Examples of devices from this 
risk class are examination gloves, sterile instruments and bandages [25].  
 Class II devices represent moderate risk devices. Examples of devices 
classified to this risk class are infusion pumps, surgical drapes and 
powered wheelchairs [24]. 
 The highest risk class is Class III, as these devices pose the potentially 
highest risk to the user. Most Class III devices have the characteris-
tics to support or sustain human life and are therefore the devices that 
present the highest potential risk of illness or injury to users [24].  
The FDA provides guidance documents for manufacturers to classify their 
device in a certain risk class. After identification to a certain risk class, the 
authorization procedure and the requested evidence requirements can be iden-
tified, being less stringent for Class I devices ranging up to very stringent for 
Class III devices [22]. In some cases, special provisions allow reclassification 
to another risk class if the FDA or the manufacturer disagrees with the po-
tential risk the device carries.  
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3.2.3 Procedure 
Regardless of its risk class, every medical device evaluated by the FDA has 
to be registered within the agency and has to pass the so-called general con-
trols. These general controls are regulated under the Federal Food, Drug & 
Cosmetic (FD&C) Act of January 5, 2010. The basic characteristics of the de-
vice are evaluated by the controls and its further consideration within the au-
thorization procedure is assessed. The main five elements included in the gen-
eral controls are: the compliance with the registration establishments, the de-
vice listing within the agency, good manufacturing practices (GMP), adequate 
labeling and the submission of a premarket application [26].  
After the initial general controls, medical devices may take different author-
ization pathways, based on their risk classification. Class I devices may enter 
the market based on an existing registration within the FDA and the assess-
ment through the general controls [26]. The authorization pathway for Class II 
devices demands, in addition to the general controls, further special controls. 
These special controls are often shaped specifically to the device in question 
[27].  
Class III devices have the most complex and stringent authorization. There 
are two options to obtain market entry for Class III devices.  
First, the manufacturer may submit a 510(k) notification application, assess-
ing the substantial equivalence to another, already legally marketed device 
(predicate device). This requires that substantial equivalence can be deter-
mined by comparing the performance characteristics, same intended use and 
technological characteristics of the new device to the predicate device [28]. 
The safety and effectiveness of the new device may be ensured through sub-
stantial equivalence. After the submission of the 510(k) premarket notifica-
tion, FDA has the right to review the application within 90 days. The manu-
facturer may not proceed to market the device within these 90 days, but only 
when the FDA declares the device substantially equivalent [29].  
If the Class III device is not substantially equivalent to any already legally 
marketed device, it has to apply for a premarket approval (PMA), the second 
possible authorization pathway for high-risk devices. A PMA is the FDA’s 
most complex and stringent process for medical device authorization, aiming 
at novel and high-risk devices. Within the process, the FDA assesses the safety 
and effectiveness of the device based on studies submitted by the manufac-
turer. The FDA requests that the application contains sufficient valid scien-
tific evidence to be able to evaluate the safety and effectiveness of the device 
within its intended use [30].  
The PMA is reviewed by a subdivision of the FDA, the CDRH, and entails 
four steps [23].  
 First, the FDA conducts a limited scientific review to conclude whether 
the application is complete and contains all required information nec-
essary for further review. Within 45 days, the applicant receives a no-
tification of completeness of the application by the agency.  
 Secondly, qualified FDA personnel will start an in-depth scientific and 
regulatory review and a quality system review. During this review the 
FDA is entitled to contact the applicant and request more information 
that is needed to complete the assessment. Within 100 days, a meeting 
can be arranged between the FDA and the applicant to discuss the 
status of the PMA process.  
registration with the 
agency is obligatory  
for every device 
 
device has to undergo 
general controls  
different authorization 
pathways 
class I – registration  
and general controls  
class II – registration, 
general controls and 
special controls  
class III –  
510(k) notification 
application for 
substantial equivalence 
class III – 
PMA/premarket 
approval for the 
assessment of safety 
and effectiveness of  
the device 
CDRH:  
4-step process 
assessment of 
completeness 
in-depth scientific 
review by FDA staff 
Evidence requirements  
for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada 
22 LBI-HTA | 2013 
 Subsequently, an external panel review will take place; the PMA is re-
vealed to an external advisory committee for review and recommen-
dations. In a public meeting, the advisory committee is asked to dis-
cuss the PMA and later submit a final decision document, including 
the recommendation of the committee and the basis for such a recom-
mendation, to the FDA.  
 The final and fourth step of the PMA process involves the final delib-
eration, documentation, and the notification to the manufacturer of the 
decision by the FDA on the device. After a device receives approval, 
the FDA publishes the approval order, labeling guidelines, and a sum-
mary of safety and effectiveness data (SSED) on its homepage.  
 
3.2.4 Evidence requirements 
The FDA requests a minimum standard of evidence for the different risk-
class-based authorization procedures. The general controls affect every med-
ical device, regardless of its risk class, and require information related to adul-
teration; misbranding; device registration and listing; premarket notification; 
banned devices; notification, including repair, replacement, or refund; records 
and reports; restricted devices; and good manufacturing practices. The man-
ufacturer is asked to independently submit this information within the ap-
propriate format provided on the FDA homepage [26].  
Special controls for Class II devices often request evidence especially tailored 
to the device in question [27].  
Minimum evidence requested for the 510(k) procedure mainly focuses on the 
substantial equivalence. The device is only substantially equivalent if it has 
the same intended use and very similar technological characteristics as the 
predicate. In the case of minor changes to the technological characteristics of 
the new device, substantial equivalence can only be ensured for an evidence 
submission containing a detail description of the changes and an adequate ex-
planation why safety is not jeopardized. It is not intended by the FDA that a 
claim of substantial equivalence anticipates that the devices are identical; it 
is rather that evidence about intended use, design, energy used, or delivered 
materials, chemical compositions, manufacturing processes, performance, safe-
ty, effectiveness, labeling, biocompatibility, standards and other characteris-
tics are suggested to be equivalent [28].  
A PMA has certain additional administrative elements and evidence require-
ments [31]. Generally, PMA documents have to contain an introduction about 
the applicant, the device, alternative practices and procedures to the device 
and the marketing history. In addition to this information, a summary of all 
studies associated with the device should be included. The FDA obliges ap-
plicants to include a technical section in the PMA [32]. The technical sections 
can be subdivided into the non-clinical laboratory studies section and the clin-
ical investigation section. Evidence required to be included in the non-clin-
ical laboratory studies section are information on microbiology, toxicology, 
immunology, biocompatibility, stress, wear, shelf life, and any further labor-
atory or animal tests [33].  
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In the clinical investigation section, information on the study protocols, safety 
and effectiveness data, adverse reactions and complications, device failure and 
replacements, patient information, patient complaints, tabulations of data 
from all individual subjects, results of statistical analyses, and any other in-
formation from the clinical investigations is required. The FDA has 180 days 
to review the PMA application and either grants or deny the market clear-
ance. Once a Class III device has failed to meet the PMA requirements, it is 
considered adulterated and cannot be marketed [31].  
Table 3.2-1: Summary of the authorization system characteristics in the USA 
Regulatory Body  Centralized system – Food and Drug Administration,  
Center for Devices and Radiological Health  
Classification  Risk class approach – Class I, Class II and Class III 
Procedure  Class I Class II Class III 
General controls General controls General controls 
 Special controls 510(k) – Substantial equivalence 
  PMA – New technology 
Evidence  
Requirements 
General  
Controls  
Special  
Controls  510(k) PMA 
 Registration  
 Device  
listing 
 GMP  
 Labeling 
 Specified 
for the 
device in  
question 
 Intended use 
 Design 
 Energy used or  
delivered materials 
 Chemical  
compositions 
 Manufacturing 
process 
 Performance 
 Safety 
 Effectiveness 
 Labeling  
 Biocompatibility 
 Any changes in 
other haracteristics 
 Introduction with alternatives, 
device history 
 Summaries of all studies 
conducted 
 Non-clinical laboratory studies: 
 Microbiology 
 Toxicology 
 Immunology 
 Biocompatibility 
 Stress wear 
 Shelf life 
 Laboratory,  
animal test summaries  
 Clinical investigation section:  
 Study protocols 
 Safety 
 Effectiveness 
 Adverse reactions and 
complications 
 Device failure and 
replacements  
 Patient information 
 Patient complaints 
 Data from all individual 
subjects 
 Statistical analyses 
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3.3 European Union: NB/Notified Bodies 
In the European Union, the core regulatory framework of medical devices is 
based on three important directives [6, 12, 13]: 
 the Directive for active implantable devices  
(AIMD, 90/385/EEC, 20th of June 1990),  
 the Directive for medical devices  
(MDD, 93/42/EEC, 1st of January, 1995), and  
 the Directive for in vitro diagnostic medical devices  
(IVDD, 98/79/EC). 
The aim of these directives is to ensure the protection of human health and 
safety within a well-functioning European Single Market. Every medical de-
vice, under a wide range of other products from different groups, has to carry 
the Conformité Européene (CE) marking before being able to legally enter 
the European market [34]. The regulatory framework established through the 
three directives aims at providing a dual purpose. On the one hand, it sets 
European-wide regulatory requirements for manufacturers of medical devic-
es to access the EU market. On the other hand, it provides device users with 
a high level of confidence in the safety and performance of the marketed prod-
ucts. The directives must be recognized and implemented in each European 
Member State through an appointed competent authority [35].  
Currently, the European Commission is revising the medical device direc-
tives. A press release and a summary with the major changes were published 
on September 26, 2012. A proposal for a regulation on medical devices, aim-
ing at replacing the Directive 90/385/EEC regarding active implantable med-
ical devices and Directive 93/42/EEC regarding medical devices was pub-
lished. Further, a proposal to replace the existing Directive 98/79/EC regard-
ing in-vitro diagnostic medical devices was submitted. The aim of these pro-
posals is to ensure that products are safe and can be freely and fairly traded 
throughout Europe. The European Commission has listed a number of points 
that have been improved in the published proposals [36]:  
 Wider, clearer scope for EU legislation – extended to include, e.g., 
implants for aesthetic purposes; clarification provided with regards to 
genetic tests  
 Stronger supervision of independent assessment bodies – conducted 
through national authorities  
 More power for assessment bodies – insurance of thorough testing 
and regular checks on manufacturers  
 Clearer rights and responsibilities for manufacturers, importers and 
distributors  
 Extended database on medical devices for information exchange on a 
European level  
 Better traceability of medical devices  
 Stricter requirements for clinical evidence during the conformity 
assessment of medical devices  
 Update on risk classification rules  
 Better coordination within European authorities  
 International guidelines to be incorporated into EU law. 
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The European Commission states that patients, healthcare professionals and 
manufacturers will benefit from the proposed changes. Currently, the pub-
lished proposals are in the revision period. 2014 is targeted as the adoption 
year and the changes should then be implemented in national practices be-
tween 2015 and 2019 [37].  
As an answer to the published proposals, a petition was written by a group of 
European healthcare experts, clearly stating that major improvements can be 
recognized in the proposals, but that further changes have to be adapted to 
ensure a high-quality and safe patient access. The petition has three main 
reasons for disagreement with the proposals and presents solutions [38]:  
 Decentralized regulatory system and the independence of the regulator 
 Centralized approval for high- and medium-risk devices conducted 
by a new public body similar to the EMA 
 Lack of requirements for evidence of clinical and patient benefit  
Proper scientific assessments of clinical and patient benefits and harms 
in short-term and long-term results from well-designed clinical studies  
 Lack of transparency in the authorization process and the results  
Publication of all information on the process and basis for approvals of 
medical devices  
The European Medical Device Directive was updated and implemented with 
the requested changes on September 24, 2013. It is intended that the new 
regulation will be adopted by 2014 throughout Europe.  
 
3.3.1 Regulatory body 
Every European Member State has a so-called competent authority. This 
competent authority constitutes the regulatory and administrative head of 
the national Notified Bodies. The main responsibility of these Notified Bod-
ies is to conduct the conformity assessment, the premarket evaluation for 
medical devices aiming to enter the European Single Market. If the products 
fulfill the essential requirements and consequently pass the conformity as-
sessment, the notified body labels these products with a so-called CE mark-
ing [7].  
A Notified Body is a for-profit organization and not every European Member 
State is obliged to administer such a body. In some cases, a national medicine 
agency serves the role, whereas other Member States do not have any institu-
tion serving as a Notified Body installed [39]. These Notified Bodies are not 
only responsible for the evaluation of medical devices, but also for other prod-
ucts such as toys and construction material that are applying for the CE mark-
ing. Approximately 168 accredited Notified Bodies exist within Europe. The 
competent authority of each European Member State is entitled to affirm a 
Notified Body within the Member State for the performance of the conform-
ity assessment as outlined within the EU directives [40].  
The manufacturer may freely choose the Notified Body that conducts the con-
formity assessment for the device in question. In addition, manufacturers are 
entitled to work with several Notified Bodies for different medical devices and 
their separate conformity assessments. The European Commission provides 
guidance documents for the Notified Bodies with standard procedure sum-
maries for the conformity assessment. It is crucial to recognize these standards 
and follow them to facilitate European-wide standardized assessments [34].  
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3.3.2 Classification 
Medical devices are categorized into four different risk classes to determine 
the appropriate evidence level for the conformity assessment. Their classifi-
cation is based on different criteria such as the intended use, the duration of 
contact with the patient, the degree of invasiveness and the part of the body 
affected by the use of the medical device. The existing risk classification is 
Class I, Class IIa, Class IIb and Class III [41].  
 Class I devices represent the lowest potential risk to consumers, with 
devices being basic medical examination tools such as stethoscopes.  
 The Class IIa category represents moderate potential risk devices, 
e.g., dental fillings.  
 Class IIb and Class III devices are generally devices that have the 
characteristics to be placed within the body with a potential invasive 
surgery. 
 Class III devices often carry the characteristic of being life sustaining 
and are therefore the high-risk devices.  
The classification to a certain risk class by a Notified Body concludes the fur-
ther regulatory assessment. For the low-risk devices, assessment starts with a 
self-certification of required evidence. A more thorough assessment is required 
for high-risk devices [42].  
 
3.3.3 Procedure 
The procedures for the conformity assessment and the rules for the affixing 
and use of the CE marking are codified in the three European Core Directives 
mentioned in chapter 3.3. All medical devices, regardless of their risk class, 
have to fulfill some general requirements [43]. In order to sign an EC decla-
ration of conformity, the manufacturer must verify that the new device ful-
fills safety and performance requirements and that it is appropriately labeled, 
providing the user with all relevant information. The conformity assessment 
modules are divided into full quality assurance system, type of examinations 
and products or production quality assurances [44].  
If the general requirements are fulfilled, the risk class of the device in ques-
tion determines the further regulatory pathway. Manufacturers of low-risk 
class devices, Class I devices, are entitled to verify through self-certification 
that the medical device conforms to the safety and performance standards set 
in the European directives. The device may therefore legally enter the market 
based on the manufacturer’s self-assessment[45].  
For moderate- and higher-risk devices, Class IIa, Class IIb and Class III, a No-
tified Body has to be appointed to perform the conformity assessment. With-
in the conformity assessment, the Notified Body verifies and assesses whether 
EU safety and performance standards are fulfilled. The NB focuses on the clin-
ical evaluation that supports the clinical safety and performance of the device 
when used as intended by the manufacturer. Clinical investigation must be 
performed to confirm or refute the manufacturer’s claims for the device [46].  
Further, the essential requirements set out in the EU core directives are eval-
uated. The main focus of these essential requirements lays on the technolog-
ical characteristics of the device. It is important to recognize that clinical ef-
ficacy is not taken into account during the conformity assessment [39].  
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Once a Notified Body has labeled a product with the CE marking, it does not 
need any additional approval or certification to enter the entire European 
Market. It may be that the device has to fulfill requirements of national reg-
ulatory frameworks and the manufacturer should be aware of these possible 
additional requirements [47]. 
 
3.3.4 Evidence requirements 
A set of requirements from the Directive 93/42/EEC is outlined in Annex I. 
These requirements can be divided into two parts: general requirements and 
essential requirements [6].  
The general requirements focus on the presentation of safety and performance 
studies. It is stated that the medical device should perform safely in its in-
tended use and should not compromise human health in any situation [48]. 
Further, the essential requirements focus on the design and construction, data 
concerning the chemical, physical, and biological properties, infection and 
microbial contamination, construction and environmental properties, label-
ing and information leaflet for users. In the case that a measuring function 
or radiation is implemented in the device, more information is requested on 
those properties. These data sets should be submitted to the Notified Body 
for the conformity assessment [49].  
Notified Bodies may ask the manufacturer to submit data from published 
clinical investigations or other studies of similar devices, so-called equivalence 
data. Moreover, Notified Bodies are entitled to review the facilities of the 
manufacturer and evaluate the compliance with the essential quality require-
ments for good manufacturing [34].  
Table 3.3-1: Summary of authorization system characteristics in Europe 
Regulatory body  Decentralized system – Notified Bodies across Europe  
Classification  Risk class approach – Class I, Class IIa and IIb and Class III 
Procedure Class I  Class IIa Class IIb Class III 
General 
requirements General requirements General requirements General requirements 
Self-certification Essential requirements Essential requirements Essential requirements 
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 Information about measuring function  
 Information about protection against 
radiation  
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3.4 Australia:  
TGA/Therapeutic Goods Administration 
The core legal frameworks that serve as the basis of medical device regulation 
in Australia are the Therapeutic Goods Act (1989), the Therapeutic Goods 
Regulations (1990), and the Therapeutic Goods Regulations (2002). These leg-
islative frameworks adopt the philosophies of the Global Harmonization Task 
Force (GHTF), an international pilot project to achieve greater uniformity 
between national medical device regulatory systems [50]. One centralized body, 
the Therapeutic Goods Administration (TGA), holds the responsibility in the 
medical device sector. The main aim of the TGA is to apply scientific and 
clinical expertise to decision making while ensuring that the benefits to con-
sumers outweigh any risks associated with the use of medical devices [51]. 
The TGA has developed the so-called Australian Regulatory Guidelines for 
Medical Devices (ARGMD) to provide guidance to the manufacturers and 
sponsors (persons with the legal obligation of the authorization application) 
of medical devices. Further, the ARGMD should help to ensure that all medi-
cal device applications to the TGA meet the necessary regulatory requirements 
and conform with the clarity and transparency standards, so that market en-
try is not delayed [50].  
 
3.4.1 Regulatory body 
In Australia, the Therapeutic Goods Administration holds the responsibility 
for the authorization of medical devices. It is accountable for the regulation 
of medicines and therapeutic goods. The TGA is part of the Australian Gov-
ernment Department of Health and Ageing. It is a centralized body and has 
developed the Australian Regulatory Guidelines for Medical Devices to out-
line the various phases within the lifecycles of medical devices [52].  
Within the TGA, the Office of Devices Authorization (ODA) is the main 
reviewing body for premarket applications. The agency is based upon scien-
tific expertise in close collaboration with healthcare professionals and indus-
try [52].  
 
3.4.2 Classification 
The TGA classifies medical devices into four risk classes with seven risk cat-
egories. The approach is based on the potential risk the device poses to the 
consumer and on the device characteristics [50].  
 The lowest risk class is Class I, and includes devices such as examina-
tion gloves. Within the Class I, a distinction is made between general 
Class I devices, Class I sterile devices and Class I measuring devices. 
Class I sterile devices have certain characteristics that have to be main-
tained in a sterile setting, and Class I measuring devices include a 
measuring function in their device technology.  
 The second main risk classification includes Class II devices: A distinc-
tion based on the potential risk the medical device poses to the con-
sumer into Class IIa and Class IIb has to be made within this class. 
All Class II devices carry a moderate risk character.  
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 The third main risk classification is devices from Class III. High-risk 
devices are included in this class. 
 The last risk class is active implantable devices (AIMD), which carry 
the highest potential risk to the user, as they often support or sustain 
life.  
 
3.4.3 Procedure 
Before any medical device may be supplied on the Australian market, the 
TGA needs to administer the Therapeutic Goods Act and the associated leg-
islation through an assessment of the device. As Australia is governed by a 
Commonwealth (Federal) government and six State and two Territory gov-
ernments, the TGA provides a uniform national standard for the authoriza-
tion of medical devices, which may have additional legislative characteristics 
within the separate State or Territory legislations [51].  
The Office of Devices Authorization, a subdivision within the TGA, reviews 
the pre-market authorization application of medical devices. The assessment 
level of medical devices performed by the ODA depends on the potential risk 
the device presents to patients. The manufacturer has to send an application 
to the TGA for inclusion into the Australian Register of Therapeutic Goods 
(ARTG). The ARTG is a register of therapeutic goods accepted for supply and 
use in Australia. It is important to recognize that only an Australian sponsor, 
who carries the legal responsibility of the medical device, can apply to be in-
cluded into the ARTG [52]. 
There are two main processes for medical devices to be included in the ARTG: 
a process for Class I devices and a process for all devices other than Class I. 
It is important to outline that Class I sterile and Class I measuring devices 
fall under other devices than the Class I category [50].  
Manufacturers of Class I general devices are asked to apply a conformity as-
sessment to their device and prepare an Australian Declaration of Confor-
mity. Yet, these documents do not have to be submitted to the TGA. The man-
ufacturer is asked to apply for the inclusion into the ARTG, but only the ap-
plication form is needed. Successful applications will result in an “automatic” 
inclusion into the ARTG. However, after inclusion into the ARTG, the manu-
facturers may have to provide the evidence to the TGA upon request [50].  
For all other devices than Class I devices, the evidence has to be submitted to 
the TGA before the application for inclusion into the ARTG. Two main things 
have to be submitted and approved before lodging an application: first, the 
conformity assessment evidence and, secondly, the evidence of compliance 
of the device with the so-called essential requirements. The key elements of 
these principles are quality, safety, and performance. After these documents 
have been accepted, the manufacturer may apply for inclusion into the ARTG 
[50].  
 
3.4.4 Evidence requirements 
The TGA bases the required evidence on the risk class of the device in ques-
tion. Manufacturers of Class I devices do not have to submit any evidence at 
the moment of application. After inclusion into the ARTG, the TGA may re-
quest a conformity declaration.  
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All other devices have to submit evidence of conformity assessment and com-
pliance with the essential principles before applying for the inclusion into the 
ARTG. 
Within the conformity assessment, the TGA request information about the 
general details of the device, the application scope, whether it is a new de-
vice, a device like one that already exists, or a recertification, the manufac-
turer’s details, including facility, and whether the device has already been 
marketed in other countries and received certification. Further, a critical sup-
plier’s form has to be filled in, and more details about the device are request-
ed. All these evidence documents have to be submitted via an online form on 
the TGA homepage [50].  
The essential principles can be divided into general principles and the design 
and construction principles of the device. The general principles include evi-
dence about the intended use, the safety principles, especially long-term safe-
ty, the transport and storage, as well as the risk ratio. The design and con-
struction principles contain evidence about chemical, physical and biological 
properties, infection and microbial contamination, construction and environ-
mental properties, measuring function or radiation, information supplied by 
the manufacturer and all relevant clinical evidence [52]. 
Table 3.4-1: Summary of authorization system characteristics in Australia 
Regulatory 
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3.5 Canada: Health Canada and the  
TPD/Therapeutic Produtcs Directorate 
Health Canada is the regulatory agency responsible in all matters related to 
maintaining and improving the health of Canadian citizens. The agency has 
the task of testing, approving, regulating and monitoring all health-related 
activities within Canada. In the medical devices sector, Health Canada is the 
enforcing body of the existing medical device regulations. Medical device reg-
ulations are based on risk management philosophy. The highest priority of 
the agency is to ensure the patient safety and effectiveness of medical care 
administered within the Canadian healthcare system [53].  
 
3.5.1 Regulatory body 
The Medical Devices Bureau of the Therapeutic Products Directorate (TPD) 
is a department of Health Canada, the national agency responsible for the 
monitoring and evaluation of diagnostic and therapeutic medical devices. Be-
sides medical devices, this federal authority regulates pharmaceuticals as well. 
The TPD is one of the seven operational directorates of the Health Products 
and Food Branch division of Health Canada. A device license listing within 
the authorization process can only be granted by the TPD [54].  
 
3.5.2 Classification 
In the Canadian medical device sector, products are grouped into four distinct 
risk classes. Every device has to be categorized before being able to enter the 
market. The approach assesses the potential risk the device carries for its user 
and determines the appropriate risk class. The approach is very similar to the 
European classification [55].  
 Class I devices are the low-risk devices, e.g., thermometer, laboratory 
culture media and some surgical instruments.  
 Class II and Class III are the moderate-risk devices like contact lenses.  
 The last risk class, Class IV, includes the devices with the highest 
potential risk for the consumer, e.g., pacemakers.  
Based on the classification into the appropriate risk class, the TPD may re-
quest different evidence within the premarket authorization process.  
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3.5.3 Procedure 
The TPD is the main reviewing body of medical devices. The agency aims to 
ensure the safety, effectiveness and quality of medical devices that are mar-
keted in Canada. This is realized by the TPD through a process of premarket 
approval, post-approval surveillance and quality systems in manufacturing 
processes.  
In order to obtain a license from the TPD, the manufacturer must first be 
accredited with a Notice of Compliance (NOC) by Health Canada. Devices 
that fall into Class I have to apply through the TPD for a so-called Establish-
ment License. That means that the TPD is aware of the establishments that 
are manufacturing and selling medical devices. To obtain an Establishment 
License, no clinical evidence is required. The devices that fall into risk Class II, 
Class III and Class IV are obliged to obtain a Medical Device License before 
being able to enter into the market. To obtain that License, the manufacturer 
has to submit a Medical Device License Application; the amount of informa-
tion being submitted varies depending on the risk class of the device. Request-
ed evidence mainly focuses on safety and effectiveness in Class II devices, ad-
ditional information on labeling and packaging in Class III, while the high-
est evidence standards for Class IV require additional information on quality 
and risk management assessments [55]. 
The three device groups all undergo an administrative review, which deter-
mines whether the device is acceptable for the application validation process. 
If recognized as acceptable, Class II devices undergo the application validity 
assessment and the license is either issued or rejected based on the presented 
information. In the case of Class III and IV devices, the application validity 
assessment is followed by a technical review, either determining the issuing 
or rejection of the license. Generally, the TPD completes the approval pro-
cedure within 75 to 90 days, and announces whether the Device License is 
issued or rejected. Throughout the whole procedure, information exchange 
and additional evidence requirements from the manufacturers are commu-
nicated [55].  
 
3.5.4 Evidence requirements 
The evidence requested by the TPD within the review of the application var-
ies between the different medical device risk classes. In general, all evidence 
requirements focus on the key elements of safety, efficacy/effectiveness and 
quality [54].  
Class I devices are not subject to any regulatory review with associated evi-
dence requirements. However, manufacturers are required to confirm that the 
product facilities have standards installed for the documentation of proce-
dures for the distribution, the handling of complaints and the product recalls.  
The evidence requirements for Class II devices focus mainly on safety and 
effectiveness standards the device ought to fulfill. That includes that a senior 
official of the manufacturer has to attest through technical documentation 
that the device meets those standards [55].  
Class III devices undergo a more complex and in-depth review. Manufactur-
ers are requested to submit summaries of all studies that have been conducted 
to assess the safety and effectiveness of the device in question. Moreover, in-
formation about labeling, packing and production are requested. To obtain 
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market approval for a Class III device, the manufacturer must include a qual-
ity of management certificate that ensures that certain standards are satisfied.  
Class IV devices have the most complex and thorough approval process and 
the highest evidence requirements. In addition to the evidence requirements 
from Class I – Class III, information about a risk assessment, the quality plan 
and the manufacturing process are requested in Class IV [55]. 
Table 3.5-1: Summary of authorization system characteristics in Canada 
Regulatory body  Centralized body – Health Canada with the Therapeutic Products Directorate  
Classification  Risk class approach – Class I, Class II, Class III and Class IV  
Procedure Class I Class II Class III Class IV 
Establishment  
License  
Medical Device 
License Application  
Medical Device 
License Application 
Medical Device 
License Application 
Evidence  
requirements  
Establishment License Medical Device License  
 General details 
 Documentation for distribution 
 Mechanisms of complaints and  
product recalls 
 General details  
 Safety standards 
 Effectiveness  
 Summaries of all studies  
 Labeling 
 Packaging  
 Production  
 Quality management certificate  
 Risk assessment  
 Manufacturing process  
 
 
3.6 Summary of premarket approval characterictics – 
Similarities and differences 
Within the four selected regions, different approaches have been set as the 
regulatory basis for the authorization process of high-risk medical devices. In 
order to provide an overview, the processes explained above are summarized 
in Table 3.6-1.  
Every system has an authorization instrument installed that serves as a mar-
ket entry label. In the European Union, products have to carry the CE mark-
ing, whereas in the United States of America products have to hold the certi-
fication of the FDA. In Australia, an inclusion in the ARTG listing and the 
receiving of a number enables the manufacturer to legally market the product. 
In the Canadian system, the product receives a license after a successful pre-
market application submission.  
The standards of approval vary, whereas the largest difference can be observed 
in the comparison between Europe and the other three analyzed systems. In 
the USA, Australia and Canada, similarities can be observed in the require-
ments for clinical evidence of safety and effectiveness as a standard for ap-
proval. On the contrary, the European system focuses on safety and perfor-
mance alone and takes neither efficacy nor effectiveness into account. This 
might change in the near future, but how it will go is not known yet. 
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The evidence required does appear – at first sight – quite similar throughout 
the description of all systems. Yet, it has been recognized that the quality and 
depth of the minimum evidence basis for the approval of a device differs. The 
FDA, considered as the most stringent authorization body among the four, 
always aims for the highest evidence level – randomized controlled trials. In 
Europe, Notified Bodies seem to accept devices and grant the CE marking 
requesting little clinical evidence. Yet, limited information is available due 
to a lack of transparency within the approval process.  
The approval is granted in the USA, Australia and Canada by one centralized 
body. This body generally assesses the device and reviews the submitted ap-
plication. In contrast, Notified Bodies all over Europe are accredited to assess 
the conformity of the device. The system is highly decentralized and manu-
facturers may freely choose the Notified Body for the assessment.  
The approval decision in the USA, Australia and Canada is publicly available 
on the homepages of the relevant regulatory authorities. Yet, only the approv-
al for PMA or 510(k) clearance (USA), the ARTG number (Australia), or the 
Device License (Canada) can be accessed. Evidence that has been submitted 
as the basis for the decision is rarely available. The EU has the least transpar-
ent system with decentralized NBs, no information access point (website) with 
data on if, where and when a medical device has received market approval 
(CE marking).  
Table 3.6-1: Evidence requirements in the four selected authorization systems 
 Europe USA Australia  Canada 
Approval 
granted by 
Notified Bodies, for-
profit organizations  
Central regulatory  
authority – FDA  
Central regulatory 
agency – TGA  
Central regulatory 
agency – Health 
Canada 
Authorizatio
n instrument 
CE Marking 
(Compliance Label)  
Premarket 
Authorization (PMA) 
or Marketing 
Clearance (510k) 
ARTG inclusion with 
number  
Device license  
listing  
Standard for 
approval  
 Safety 
 Technical  
performance  
PMA: 
 Safety  
 Effectiveness  
510(k):  
 “substantial  
equivalence”  
 Risk ratio 
 Safety/long-term 
safety  
 Effectiveness  
 Benefits to 
patients  
 Safety  
 Effectiveness  
Evidence  
required  
 Laboratory 
testing 
 Literature  
reviews  
 Small clinical 
trials  
 Clinical trials  
generally 
randomized and 
controlled  
 Risk analysis  
 Literature 
searches  
 Clinical trials  
 Expert opinion  
 Summary of all 
studies  
 Bibliography of 
all published 
reports  
Transparency 
of approval  
decision  
No public 
information  
Approval and 
evidence is publicly 
available 
ARTG listing publicly 
available  
Device license  
listing publicly  
available  
 
 
highest evidence 
standard are RCTs  
centralized body in USA,  
 
Canada and Australia 
decentralized in EU 
information on 
marketed devices 
publicly available: USA, 
Canada, and Australia 
 
no information from 
NBs in EU 
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4 Clinical evidence for seven selected 
medical devices – Authorization 
This chapter introduces the evidence available at the time of authorization 
and approval for the seven medical devices selected for the purpose of this re-
search. The four regulatory bodies in charge of the authorization processes for 
medical devices in the European Union, the USA, Australia and Canada were 
contacted about the evidence submitted within the premarket application for 
each of the seven devices. Further, the respective manufacturers were informed 
about the research and asked to present the relevant evidence documents for 
the devices that were submitted to the authorization institutions. In addition, 
a literature search for each of the devices was performed and the internation-
al clinical trial database (clinialtrial.gov) was scanned for more information 
on clinical trials conducted for the device. The results for each medical device 
are provided in the following.  
Table 4-1: Authorization status of the seven exemplary medical devices 
Medical Device  CE marking  FDA application  Inclusion in ARTG License by TPD Manufacturer 
Zephyr®  
Endobronchial 
Valve  
Yes (2003) Rejection 
(2008)  
No application 
submission;  
similar device 
(2011) by  
Olympus Australia  
No application 
submission 
PulmonX –  
Interventional 
Pulmonology  
Paracor Ventri-
cular Support  
System (PVSS) 
Yes (2000) Rejection 
(2000)  
No application 
submission 
No application 
submission 
Paracor  
Medical Inc.  
Annular repair  
device Barricaid® 
Yes (2009) No application 
submission 
Yes (2011)  No application 
submission 
Intrinsic  
Therapeutics, Inc. 
Rheofilter  
ER-4000 
Yes (1998) No application 
submission 
No application 
submission 
Rejection  
(Yes from  
2002 – 2005)  
Asahi Kasei  
Medical Co., LTD.  
BSD-2000  
Microwave  
Hyperthermia  
System  
Yes Rejection 
(Only under 
HDE since 2011) 
No application 
submission 
No application 
submission 
BSD Medical Inc.  
Amplatzer™ PFO 
Occluder 
Yes  Rejection 
(Only under 
HDE until 2006)  
Yes (2006)  Yes (2001)  St. Jude Medical  
MitraClip® Yes (2008)  Yes (2013) Yes (2010)  No application 
submission 
Abbott  
 
 
  
evidence from 
regulatory bodies, 
manufacturers, 
literature search and 
clinical trial database  
for the 7 devices  
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4.1 Zephyr® Endobronchial Valve 
The following section provides information on the Zephyr® Endobronchial 
Valve. The device is produced by the company PulmonX. It is currently on 
the market in Europe only.  
 
4.1.1 Indication 
The Zephyr® Endobronchial Valve is a device designed for the treatment of 
Emphysema, a chronic disease of the lungs. Emphysema is a disabling, irre-
versible and progressive disease that decreases the tolerance to active exer-
cise and impairs the quality of life. The disease has the characteristic that it 
is poorly responsive to medical interventions. Through structural changes in-
duced into the lung system, the regular airflow is hindered. Emphysema re-
sults into a decrease in lung elastic recoil that subsequently increases the ex-
piratory airflow resistance. Consequently, the exchange of the life-supporting 
gases in the alveoli is impaired. The lungs are suffering from a dynamic hy-
perinflation. This hyperinflation progresses rapidly. Complications associat-
ed with emphysema are breathlessness, low tolerance to physical activity, de-
creased chest wall and muscle function mechanics, prolonged respiratory fail-
ure and increased mortality. Emphysema is categorized within the class of 
chronic obstructive pulmonary diseases (COPD). The Zephyr® Endobron-
chial Valve aims at controlling the airflow through pointed placement of sev-
eral valves into the diseased airways of a particular lung loop [56].  
 
4.1.2 Mechanic procedure 
The valve is a sterile, single-use system consisting of three parts: the Zephyr 
EBV valve, the Zephyr ELS loader system and the Zephyr EDC delivery cath-
eter. The valve is an implantable, one-way, silicone valve. It entails a self-
expanding stent structure that inflates in the diseased lung lobe. Once im-
planted, the valve intends to prevent airflow into the hyper-inflated regions 
of the lung while still allowing airflow out of them. The valve is implanted 
through a delivery catheter that includes a loader system for the compressed 
valve at its distal end. The delivery catheter is passed through a bronchoscope 
to place the valve in the bronchial loop [57].  
 
4.1.3 Accessible evidence 
The device obtained CE marking in 2003. A very similar device is on the mar-
ket in Australia, but no specific information about the Zephyr valve is acces-
sible. In the USA, the device was rejected for approval in 2008; no applica-
tion for a device license listing was found in Canada. All accessible evidence 
is summarized in Table 4.1-1.  
 
Zephyr currently on the 
market in Europe only  
device designed  
for the treatment  
of emphysema: 
a chronic disease  
of the lungs 
Zephyr is an implantable, 
silicone valve  
2003 CE marking, 
rejection FDA 2008  
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Table 4.1-1: Available evidence for market approval of Zephyr® Endobronchial Valve (extracted 26.03.2013) 
Studies by 
year Level of evidence FDA ARTG 
TPD  
(no application 
submitted) 
Notified 
Bodies 
Literature 
Search 
Clinical 
trials 
Herth et al., 
2012 
Open label, randomized, 
multicenter trial  
(VENT Europe)  
- NA / NA √ - 
Sciurba et al., 
2010  
Open label, randomized, 
multicenter trial  
(VENT reporting)  
√ NA / NA √ √ 
Lee et al., 2010 Case series  - NA / NA √ - 
Herth, 2008 Safety and Efficacy study - NA / NA  √° 
Strange et al., 
2007 
Study design: Open label, 
prospective, randomized, 
multi-center trial (VENT) 
√ NA / NA √ √ 
Wan et al., 
2006 
Retrospective analysis 
from prospective 
multicenter registry  
- NA / NA √ - 
Hopkinson  
et al., 2005 
Case series  - NA / NA √ - 
Leroy and 
Marquette, 
2004 
Announcement of 
planning of the VENT trial  
- NA / NA √ - 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
 
FDA 
In the United States of America, the FDA evaluated the evidence available 
for the Zephyr® Endobronchial Valve in a panel discussion of the Anaesthe-
siology and Respiratory Therapy Devices committee in 2008. The panel voted 
11:2 that the premarket approval application of the Zephyr® Endobronchial 
Valve was found “not approvable.”  
The FDA documents used during the panel discussion provide five clinical 
studies [58].  
 The VENT (Endobronchial Valve for Emphysema PalliatioN Trial) is 
an open-label, randomized, multicenter trial comparing the Zephyr 
EBV system to optimal medical management controls. Strange et al. 
published the results of the trial in 2007.  
 The Zephyr EBV Europe was conducted between June 2004 and Jan-
uary 2006; 171 subjects were enrolled and randomized (2:1), with 111 
EBV-treated subjects and 60 control subjects). The demographic pro-
file and the results can be seen as consistent with those observed in 
the VENT.  
 A compassionate and emergency use study mostly for air leaks with  
a total of 65 subjects.  
 A study with the first generation version of the device EBV –  
“Over-the-wire (OTW)” with a total of 62 subjects was conducted.  
 A feasibility trial of the Zephyr EBV and the EBV-OTW with the  
inclusion of 113 subjects was conducted.  
 
FDA denied the 
premarket application 
of the Zephyr in 2008  
five clinical studies  
have been used as 
evidence basis for  
the FDA rejection  
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Notified Bodies 
The Notified Body which has been assessing the endobronchial valve is un-
known. No information about the body or about the assessment and included 
evidence was found.  
 
TGA  
The TGA has installed a tool to search manually through the ARTG to iden-
tify whether a medical device has been granted market authorization in Aus-
tralia. Using this search tool, it has been recognized that an endobronchial 
valve with very similar characteristics to the Zephyr® Endobronchial Valve 
was assessed and included into the ARTG in 2011. The manufacturer of the 
device is Spiration Inc., a US firm and the sponsor is Olympus Australia Pty 
Ltd. A public summary from the ARTG regarding this device is accessible. 
Yet, the summary only describes the device briefly and states the inclusion of 
the device into the ARTG; no evidence that was used during the premarket 
assessment can be found [59].  
From this information it cannot be extracted whether the Zephyr® Endo-
bronchial Valve has been rejected or approved and included in the ARTG in 
Australia.  
 
TPD  
The TPD has installed a search tool only for the devices that are currently on 
the market in Canada, but not for devices that have been assessed or whose 
market authorization has been rejected. Therefore, no information about an 
application or evidence submitted to the TPD within the authorization pro-
cedure is publicly available.  
 
Literature search 
A literature search in PubMed was conducted using the keywords Zephyr®, 
OR Endobronchial Valve AND emphysema. 40 hits were listed in the search. 
With a limitation to clinical trials, seven of these articles focused on the valve 
and one on the Chartis™ treatment plan.  
 In 2004, Leroy and Marquette announced the planning of the VENT 
trial [60].  
 In 2005, Hopkinson et al. published a case series including 19 patients 
[61].  
 In 2006, Wan et al. presented a retrospective analysis from a prospec-
tive multicenter registry. Included in the study were 98 patients [62].  
 In 2007, Strange et al. provided the study design of the VENT (Endo-
bronchial Valve for Emphysema Palliation Trial), a randomized con-
trolled trial planning to include 270 patients [63].  
 In 2010, Lee et al. reported about a case series including 8 patients [64]. 
 In the same year, 2010, Sciurba et al. reported about the VENT. 321 
patients were enrolled, with 220 to receive the valve and 101 to receive 
standard medical care. The trial was funded by PulmonX [65].  
 In 2012, Herth et al. reported about the VENT European cohort results, 
as well as about a randomized controlled trial including 171 patients [66].  
no evidence available – 
device marketed  
similar device marketed 
in Australia with 
different manufacturer  
no information  
about the valve  
no application 
submission of the  
device available  
1 RCT and  
several case series  
planning of VENT 
(2004)  
case series (2005) 
case series (2006) 
Study design VENT 
(2007)  
case series (2010) 
VENT reporting (2010) 
Vent Europe reporting 
(2012) 
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Clinical trial database  
The database was searched with the keywords Zephyr® OR Endobronchial 
Valve OR emphysema. The database registered several trials conducted on the 
device. 
 The VENT trial was received by the registry in August 2005 and has 
successfully been completed and published.  
 A clinical trial about sequential endoscopic lung volume reduction 
started in 2008 and was sponsored by the University of Heidelberg. 
The status of this trial is currently unknown and the estimated study 
completion date was December 2011. 
 A trial investigating the long-term effects of endobronchial valves in 
Emphysema (LIVE) was registered with clinicatrial.gov in April 2012. 
The study is sponsored by the manufacturer PulmonX Inc. It is cur-
rently recruiting participants. The estimated study completion date is 
April 2019.  
 
Figure 4.1-1: Evidence pyramid for Zephyr® Endobronchial Valve 
At the time of the approval for the CE marking for the Zephyr® Endo-bron-
chial Valve in 2003, no randomized controlled trial or another clinical study 
was available.  
All the clinical evidence found for the valve is summarized in Table 4.1-1. 
Further, the evidence is presented in an evidence pyramid (Figure 4.1-1) It 
can be recognized that the level of evidence available for the valve is one ran-
domized controlled trial and three case series. 
The rejection of the application for premarket approval from the FDA for the 
device in 2008 was based on one randomized controlled trial and four other 
clinical studies. Information about application for market entry in Canada 
and Australia has not been found.  
VENT trial (2005)  
safety and efficacy 
study (2008) 
LIVE – long-term effects 
of endobronchial valves 
in emphysema (2012)  
no clinical evidence 
available at time of  
CE marking  
1 RCT (2010) and  
3 case studies  
(2005; 2006; 2010) 
rejection by  
FDA based on 1 RCT,  
4 clinical studies 
 
SLRs 
RCTs – 1 
Cohort studies 
Case-control studies 
Case series – 3 
Case reports 
Ideas, Editorial, Opinions 
Animal studies 
In-vitro studies 
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4.2 Paracor Ventricular Support System 
(PVSS) 
The following chapter provides information about the PVSS. The device was 
produced by Paracor Medical Inc. and can only be marketed in Europe.  
 
4.2.1 Indication 
The PVSS is designed for patients with congestive heart failure to halt or re-
verse the disease process of dilated cardiomyopathy. Heart failure is a progres-
sive, chronic condition in which the heart muscle is unable to pump enough 
oxygen-rich blood through the body. The disease is associated with a high 
level of disability, morbidity and mortality. In early stages of heart failure, 
the heart tries to compensate with enlarging, developing more muscle mass 
and pumping faster. Yet, at a certain time point the heart and body reach an 
exhaustion phase and the patient experiences fatigue and breathing problems, 
among other symptoms. Due to the compensation mechanism of the body, 
many patients are not aware of the progressive heart failure until years after 
their heart function begins to decline [67].  
 
4.2.2 Mechanic procedure 
The Paracor Ventricular Support System is a prosthetic elastic mesh made 
of nitinol and silicone that can only be used in combination with a delivery 
system, a long stick in combination with an introducer being used to reach 
the ventricles. The mesh is loaded onto the delivery system and implanted 
over the epicardial surface of the right and left ventricles. It is intended to 
reduce wall stress by the application of low levels of epicardial pressure and 
consequently treat the progression of cardiomyopathy. The surgical procedure 
is described as minimally invasive. The PVSS should support the heart mus-
cle and its functions. As the homepage and the e-mail contact of the produc-
er Paracor Medical Inc. is not active, no more detailed information about the 
mechanic procedure of the PVSS is available [68].  
 
  
PVSS only on the 
European market  
PVSS designed  
to halt or reverse 
congestive heart failure  
PVSS is a prosthetic 
elastic mesh out of 
nitinol and silicone, 
implanted through a 
delivery system  
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4.2.3 Accessible evidence 
PVSS can only be legally marketed in Europe. The device was labeled with 
the CE marking in 2000. In the same year, the FDA rejected the application 
for premarket approval. No information about a submission of premarket ap-
proval application in Australia and Canada was found.  
Table 4.2-1: Available evidence for the Paracor Ventricular Support System (extracted 28.03.2013) 
Studies  
by year Level of evidence FDA 
ARTG (no 
application 
submitted) 
TPD (no 
application 
submitted) 
Notified 
Bodies 
Literature 
Search 
Clinical 
trials 
Abraham  
et al., 2012 
(HeartNet) 
Randomized controlled 
trial – Rationale and design  
NA / / NA √ - 
Constanzo  
et al., 2012 
Prospective, randomized, 
controlled multicenter 
trial – Interim analysis  
NA / / NA √ √^ 
Klodell et al., 
2007 
Case series  NA / / NA √ - 
Paracor 
Medical Inc., 
2005 
Feasibility study NA / / NA - √ 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
 
FDA 
The FDA rejected the market authorization application for the PVSS in 2000. 
However, no information was released on what basis the application was re-
jected.  
 
Notified Bodies  
In 2000, the PVSS entered the European market. No information is available 
about the Notified Body that conducted the conformity assessment and the 
evidence submitted.  
 
TGA  
The PVSS is not on the market in Australia. The ARTG was scanned and no 
listing for Paracor Medical Inc. with/or the PVSS was recognized. Further, no 
information about the submission of a premarket approval application can be 
found.  
 
TPD  
Paracor Medical Inc. has no market authorization for the Canadian market. 
Searching within the TPD database has released no information. No informa-
tion about the submission of a premarket approval application is available. 
 
  
CE marking and FDA 
rejection both in 2000 
rejection of premarket 
application in 2000 
no information available 
no premarket approval 
application 
no premarket approval 
application  
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Literature search 
A literature search with the keywords Paracor AND congestive heart failure 
was conducted. With the limitation to only clinical trials, three hits were pre-
sented.  
 In 2007, a report was published by Klodell et al. about a case series in-
cluding 21 patients. This case series focused on the HeartNet device [69].  
 In 2012, Abraham et al. reported about the rationale and the design of 
a multicenter, randomized controlled trial (PEERLESS-HF) for the 
HeartNet device. The planned enrolment was 27 patients [70].  
 In the same year, 2012, Costanzo et al. presented a prospective evalu-
ation of the PEERLESS-HF trial and reported that enrollment was 
stopped based on interim results [71].  
 
Clinical trial database  
The clinical database was searched with Paracor OR ventricular support 
system. Two registered studies were found.  
 In 2005, an early feasibility study was registered by Paracor Medical Inc. 
The study enrolled 39 patients and first results were received in 2011.  
 The PEERLESS-HF trial was registered within the database in 2006, 
but was then terminated.  
 
Figure 4.2-1: Evidence pyramid for Paracor Ventricular Support System 
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All evidence is summarized in Table 4.2-1. Furthermore, the evidence is pre-
sented in an evidence pyramid. At the time of CE marking approval and FDA 
rejection, no randomized controlled trial or clinical studies were available.  
A case series was performed seven years later. In addition, Paracor Medical 
Inc. developed the HeartNet device, which bears very similar characters to the 
PVSS. A randomized clinical trial was started for the HeartNet device, but 
soon suspended based on an interim analysis.  
 
 
4.3 Annular Repair Device Barricaid® 
The following chapter provides information about Barricaid®. The manufac-
turer of Barricaid® is Intrinsic Therapeutics. 
 
4.3.1 Indication 
The human spine consists of five lumbar discs, each of which is comprised of 
the annulus (outer ring) and the nucleus (central space) in its lower section. 
These discs help to balance out the external loads, gravity and physical ac-
tivity placed on the spine. A spinal disc herniation occurs when the annulus 
partially of fully tears apart and portions of the nucleus bulge out. Symptoms 
are generally local pain and leg pain. In about 10% of patients suffering from 
spinal disc herniation, a surgical discectomy procedure is advised. The pro-
cedure aims at relieving the pain caused from the bulging nucleus material 
and therefore takes the pressure off a certain nerve root. The success rates 
have been very high, yet major adverse events have been recognized following 
a discectomy. One major challenge is the hole, called a “defect” that a discec-
tomy procedure leaves in the annulus wall. The risk of reherniation, i.e., the 
nucleus bulges out through the already existing defect, is consequently very 
high. The Barricaid® annular repair device was designed to target the ad-
verse effects, especially to close the defects in the annulus wall subsequent to 
the discectomy procedure and reduce reherniation rates [72]. 
 
4.3.2 Mechanic procedure 
The Barricaid® annular repair device is supposed to treat larger defects of 
the annulus wall by creating a barrier for the remaining nucleus within the 
annulus wall. The device is placed within the inner surface of the disc annu-
lus and serves as a barrier/closure to stop more nuclei to leave the inner space. 
It is believed that through the implant of the Barricaid®, the damaged disc 
can be preserved. The device is formed from a flexible mesh that is made up 
of multiple layers of counter-angulated fibers. The layers are designed to mim-
ic the structure of the healthy annulus wall. The layers are sewn together and 
secured to a strong titanium bone anchor. Through that anchor the mesh is 
connected to one of the surrounding vertebral bones [73].  
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4.3.3 Accessible evidence 
The Barricaid® has been on the market in Europe since 2009 and in Australia 
since 2011.  
Table 4.3-1: Available evidence for annular repair device Barricaid® (extracted 04.04.2013) 
Studies  
by year Level of evidence 
FDA (no 
application 
submitted) ARTG 
TPD (no 
application 
submitted) 
Notified 
Bodies 
Literature 
Search 
Clinical  
trials 
Lequin et al., 2012 Prospective case  
series 
/ NA / - √ √* 
Intrinsic 
Therapeutics, 2011  
Randomized study  / NA / - - √* 
Chiang et al., 2011 Technical  
feasibility study  
/ NA / - √ - 
Intrinsic 
Therapeutics, 
2009 (received by 
manufacturer) 
Benchtop testing/ 
Biomechanical  
comparison  
/ NA / √ - - 
Gorensek et al., 
2004 
Abstract report for  
a prospective, multi-
center, controlled 
clinical study  
/ NA / - √ - 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
 
FDA 
The Barricaid® is currently not on the market in the United States of Amer-
ica and a premarket approval application has not yet been submitted. The 
manufacturer, Intrinsic Therapeutics Inc. has stated that the application for 
the market authorization will be submitted in the near future.  
 
Notified Bodies  
The manufacturer has released the information about the Notified Body re-
sponsible for the conformity assessment of the device. In 2009, the device was 
assessed by the TÜV Rheinland Product Safety GmbH, in Cologne. The cer-
tificate serves as an approval with the EC Directive 93/42/EEC Annex II, 
Article 3 – Full Quality Assurance System, Medical devices, and entitles In-
trinsic Therapeutics Inc. to market the Barricaid® legally in Europe. The cer-
tificate expired in August 2013 and the manufacturer has to ensure its re-
newal. However, the certificate does not offer any insight into the evidence 
used as a basis for the approval decision.  
 
TGA  
The device was listed in the ARTG, as stated by the manufacturer. Yet, the 
TGA was not able (willing?) to release any further information about the ev-
idence used as a basis for the decision to include the Barricaid® into the 
ARTG. The manufacturer has stated that it is believed that the ARTG inclu-
sion was based on the obtained CE marking.  
 
no premarket approval 
application has been 
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no evidence available  
CE marking basis for 
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TPD  
The TPD has not yet reviewed any evidence of the Barricaid® annular repair 
device, as the manufacturer has not yet applied for the premarket approval. 
It has been stated by the contact to Intrinsic Therapeutics that the applica-
tion will be submitted in connection with the application for the FDA.  
 
Literature search 
The literature search used the keywords Barricaid® OR lumbar discectomy 
OR reherniation. The limitation was set to clinical trials. In the literature 
search three relevant academic articles were found.  
 Gorensek et al. published an abstract report about a prospective, mul-
ticenter, controlled clinical study in 2004. This study included 15 pa-
tients with an implanted Barricaid® device [74].  
 In 2011, a technical feasibility study was presented by Chiang et al. 
The techniques were only assessed in animal models [72].  
 In 2012, an article by Lequin et al. was published describing one-year 
clinical and radiographic results from a non-randomized, partly un-
controlled study being nested in a prospective, multicenter trial. The 
study included 45 patients [75].  
 
Clinical trial database  
The clinical trial database was searched with the keywords Barricaid® OR 
lumbar discectomy. Two trials have been registered within the database.  
 A randomized study registered by Intrinsic Therapeutic in 2011, is cur-
rently recruiting patients. Estimated enrolment is 500 patients and 
study completion in 2016. 
 A multicenter EU post-marketing surveillance study published by 
Lequin et al. (described above) was registered in 2012.  
 
Figure 4.3-1: Evidence pyramid for the annular repair device Barricaid® 
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All the evidence available for the Barricaid® device has been summarized in 
Table 4.3-1. At the time of CE marking approval in 2009, only an abstract 
from a planned RCT and benchmark testing/biomechanical comparison was 
available. At the time of inclusion into the ARTG in 2011, the abstract, the 
benchmark testing and a technical feasibility study were available.  
The highest level of evidence presented in the evidence pyramid for the device 
is currently one case series.  
 
 
4.4 Rheofilter ER-4000 
The following chapter summarizes the evidence of the Rheofilter ER-4000. 
Produced by Asahi Kasei Medical Co., the device can only be legally marketed 
in Europe.  
 
4.4.1 Indication 
The Rheofilter ER-4000 is a procedure targeted at dry age-related macular 
degeneration (AMD). AMD is the leading cause of irreversible vision loss and 
blindness in patients older than 65 years in Western industrialized societies. 
The indication is a deterioration of the macula, a light-sensitive tissue lining 
the back of the eye in the central part of the retina. During the progression of 
the disease, the macula is compromised. This compression leads to a disrup-
tion of both structure and vision function. There are several forms of AMD 
and dry AMD is the most common form, amounting up to 85-90% of all dis-
eased cases. Patients may experience symptoms such as blurriness, dark are-
as, and distortion in their central vision ability. The disease might finalize in 
total loss of central vision. The aetiology of the disease is not yet fully under-
stood, but it is believed that genetic factors play a major role in the pathology 
next to risk factors such as age, gender and smoking [76]. 
 
4.4.2 Mechanic procedure 
The Rheofilter ER-4000 is part of an extracorporeal double filtration system. 
It is used in combination with a plasma separator for selective extracorporeal 
plasma therapy, e.g., Rheopheresis. The therapy involves the removal and re-
placement of blood and blood plasma. Blood is extracted from the body and 
separated into a plasma and blood pump. A plasma component separator is 
installed in the plasma pump, aiming at removing harmful and disease-caus-
ing substances while leaving all valuable substances to be returned to the pa-
tient. There are several therapeutic approaches for various indications, where-
as the blood extraction and filtration system can be adapted to the special 
needs of patients [77].  
 
evidence available at 
time of CE marking and 
ARTG inclusion 
highest level of evidence 
– case series  
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4.4.3 Accessible evidence 
The Rheofilter ER-4000 is currently only on the market in the European Un-
ion, receiving its CE marking in 1998. It had been approved in the Canadian 
system from 2002 until 2005, but was then removed from the device license 
listing. 
Table 4.4-1: Available evidence for the Rheofilter ER-4000 (extracted 15.04.2013) 
Studies  
by year Level of evidence 
FDA (no 
application 
submitted) 
ARTG (no 
application 
submitted) TPD 
Notified 
Bodies 
Literature 
Search 
Clinical 
trials 
Wild et al., 2009 Systematic literature 
review 
/ / NA NA √ - 
Klingel et al., 
2009 
Analysis of Registry – 
Safety and Efficacy study 
/ / NA NA √ - 
Koss et al., 2009 Prospective, 
randomized,  
controlled clinical study 
/ / NA NA √ - 
Choudry,  
OccuLogix Inc.,  
2007 
Multicenter, 
randomized,  
sham controlled trial 
/ / NA NA - √^ 
Kubista, Ludwig 
Boltzmann 
Institute, 2007 
Prospective case study / / NA NA - √* 
Pulido et al., 2006 Multicenter, 
randomized clinical trial 
/ / NA NA √ - 
Choudry, Occu-
Logix Inc., 2006 
Long-term efficacy 
study 
/ / NA NA - √° 
Pulido et al., 2005 Literature review / / NA NA √ - 
Siegel, OccuLogix 
Inc., 2004 
Randomized,  
double-blind clinical trial 
/ / NA NA - √° 
Koch, Apheresis 
Research 
Institute, 2003 
Prospective, 
randomized,  
controlled clinical study 
/ / NA NA - √ 
Klingel et al., 2003 Literature review / / NA NA √ - 
Brunner et al., 
2000 
Randomized controlled 
trial 
/ / NA NA √ - 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
 
FDA 
The FDA homepage was scanned without any relevant results; no infor-
mation about an application for premarket approval submission is available 
from the FDA.  
 
Notified Bodies  
No publicly available information regarding the evidence used for the con-
formity assessment from the Notified Body can be found.  
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no premarket approval 
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TGA  
The ARTG was searched for the product and/or the manufacturer. No infor-
mation about the submission of a premarket approval application or an as-
sessment of the device could be extracted in any search combination.  
 
TPD  
The Medical Device Active License Listing (MDALL) established by Health 
Canada was searched with the product name and the manufacturer. No in-
formation could be found using the product name; however, using the man-
ufacturer’s name resulted in some hits. On November 21, 1999 the Plasma-
flo-Op 05W, which is a part of the complete Rheopheresis therapy, was in-
cluded in the active device license listing of products marketed in Canada. 
No further evidence that led to the inclusion into the MDALL could be ex-
tracted [78].  
 
Literature search 
A literature search was conducted using the keywords Rheopheresis OR 
Rheofilter ER-4000. With the limitation to clinical trials only, seven results 
were identified.  
 In 2000, a randomized controlled trial including 43 patients in Ger-
many was performed by Brunner et al. The study was sponsored by 
Ashai Kasei Medical, the manufacturer of the product in combination 
with the Diamed Medzintechnik GmbH. 
 A literature review was published in 2003 by Klingel et al. [79].  
 A literature review from Pulido et al. was made available in 2005.  
 In 2006, Pulido et al. published data about a multicenter, randomized 
clinical study sponsored by OccuLogix, Inc. A total of 216 patients were 
recruited for this study [80].  
 In 2009, Wild et al. conducted a systematic literature review about the 
Rheopheresis therapy for AMD [81].  
 In 2009, Klingel et al. evaluated the RheoNet registry for the safety and 
efficacy of the Rheopheresis treatment. The registry was established 
counting 7722 Rheopheresis treatments of 1110 patients, from which 
833 were diagnosed with AMD [82].  
 Koss et al. (2009) performed a prospective, randomized, controlled clin-
ical study including 52 patients [83].  
 
Clinical trial database  
The clinical trial database was searched with the keyword Rheopheresis. Five 
relevant results were included in this research.  
 In 2003, a study was registered by the Apheresis Research Institute. 
The study design was a prospective, randomized, controlled study. 
 A study sponsored by OccuLogix was registered in 2004.  
Study design was a randomized, double blind clinical trial. 
 In 2006, OccuLogix introduced a long-term efficacy study. 
 In 2007, OccuLogix registered a multicenter, randomized,  
sham controlled study.  
 In the same year, a prospective case study was registered by  
the Ludwig Boltzmann Institute for retinology.  
no premarket approval 
application submitted  
search for the 
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the inclusion of the 
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7 articles were found  
RCT (2000)  
literature review (2003)  
literature review (2005)  
RCT (2006) 
systematic literature 
review (2009) 
RheoNet registry for 
safety and efficacy 
(2009)  
RCT (2009)  
5 trials registered  
prospective, randomized 
controlled study (2003)  
RCT (2004)  
long-term efficacy study 
(2006)  
multicenter, sham RCT 
(2007)  
prospective case study 
(2007)  
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Figure 4.4-1: Evidence Pyramid for Rheofilter ER-4000 
All the evidence accessible for the Rheofilter ER-4000 is summarized in Ta-
ble 4.4-1. At the time of CE marking approval in 1998, no randomized con-
trolled trial or other clinical studies were available. The device was included 
in the medical device licence listing in Canada from 2002-2005. At the time of 
approval in 2002, one randomized controlled trial was available.  
The evidence available for the device has been presented in an evidence pyr-
amid. Three systematic literature reviews make up the highest level of evi-
dence. Further, four completed controlled studies and one completed case 
series are available. 
 
 
4.5 BSD-2000 Microwave Hyperthermia System 
The following chapter summarizes the evidence for the BSD-2000 Microwave 
Hyperthermia System. The device is produced by BSD Medical and is on the 
market in Europe and the United States of America under a humanitarian de-
vice exception (HDE/Humanitarian Device Exemption).  
 
4.5.1 Indication 
The BSD-2000 Microwave Hyperthermia System is used in conjunction with 
radiation therapy for the treatment of cancer patients who are ineligible for 
chemotherapy. The device provides deep regional therapeutic hyperthermia 
to attack tumors by applying radiofrequency energy. It is assumed that the 
effectiveness of radiation therapy is increased while using the BSD-2000 in 
conjunction [84].  
CE marking 1998 
approval no clinical 
evidence available  
highest level of evidence, 
SLRs are available  
device currently on the 
market in Europe and 
USA under HDE 
hyperthermia system 
used in conjunction with 
radiation therapy for 
cancer patients 
 
SLRs – 3 
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Cohort studies 
Case-control studies 
Case series – 1 
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Ideas, Editorial, Opinions 
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4.5.2 Mechanic procedure 
The BSD-2000 delivers energy to a patient by using a power source and an 
array of multiple antennae that surround the patient’s body. The BSD-2000 
was designed to provide an optimized heating zone targeted to the tumor re-
gion by utilizing the adjustment of frequency, phase, and amplitude from 
multiple power sources. The energy can be focused electronically to the tu-
mor region, thus providing dynamic control of the heating delivered to the 
tumor region. During a treatment, the cancerous tumor is heated to 40°C 
and 45°C. Hyperthermia damages cells in solid tumors, without damaging 
normal tissues, because higher temperatures selectively damage cells that 
are hypoxic and have low pH, a condition of tumor cells and not a condition 
of normal cells [85].  
 
4.5.3 Accessible evidence 
The device has received the CE marking, but no information is available 
about the year in which it was received. The FDA allowed the device in 2011 
under a HDE/humanitarian device exemption. The following section pre-
sents the accessible evidence for the device.  
Table 4.5-1: Available evidence for the BSD-2000 Microwave Hyperthermia System (extracted on 16.04.013) 
Studies  
by year 
Level of 
evidence 
FDA 
(HDE) 
ARTG (no 
application 
submitted) 
TPD (no 
application 
submitted) 
Notified 
Bodies 
Literature 
Search  
Clinical 
trials 
BSD Medical 
Corporation, 2011 
Registry study 
– Benefit and 
safety 
√ / / NA - - 
Duke Medical 
Center, 2008 
Case series - / / NA - √ 
Sreenivasa et al., 
2006 
Case series  - / / NA √ - 
Jones et al., 2006 Case series  - / / NA √ - 
Hildebrandt et al., 
2004 
Case series  - / / NA √ - 
Wust et al., 2004 Case series - / / NA √ - 
Rau et al., 
1998/2000 
Case series  - / / NA √ - 
Daniel den Hoed  
Cancer Centre, 
1996 
Prospective 
randomized 
trial 
√ / / NA - - 
Wust el al. 1995 Phantom study  - / / NA √ - 
Sapozink et al., 
1990 
Case series  - / / NA √ - 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
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FDA 
The BSD-2000 was approved under a humanitarian device exemption (HDE) 
in 2011 by the FDA. The FDA stated clearly that the device can only be ad-
ministered to cervical carcinoma patients in conjunction with radiation ther-
apy. Those patients have to be ineligible for chemotherapy. The FDA based 
the HDE approval decision on the following evidence [86]:  
 Phase III prospective, randomized study. The study duration was from 
May 1990 to September 1996. A total of 65 patients were included in 
the study.  
 BSD Medical Cooperation, the manufacturer of the device, initiated a 
registry study in 2011 to provide additional evidence of the probable 
benefit and the safety of the use of hyperthermia delivered through the 
hyperthermia system in conjunction with radiation therapy for ad-
vanced cervical carcinoma.  
 
Notified Bodies  
No information about the Notified Body that assessed the BSD-2000 device 
could be found.  
 
TGA  
The device may not be legally marketed in Australia, as no ARTG listing exits. 
The ARTG listing was scanned under the device name BSD-2000 Hyperther-
mia System OR hyperthermia. Just searching with the keyword hyperthermia, 
a variety of different products from different manufacturers could be found. 
For the BSD-2000 device, no information about an application for premarket 
submission or evidence submitted could be found.  
 
TPD  
The device listing of Health Canada was searched and no entry for the BSD-
2000 Hyperthermia System was found. Further, no information about the sub-
mission of a premarket approval application could be extracted. However, as 
in the ARTG of Australia, scanning the listing with only the keyword of hy-
perthermia detected some hits. As in Australia, where various companies have 
legally marketed a hyperthermia system, in Canada only Belmont Instrument 
Cooperation is listed within the device licenses. However, BSD Medical Co-
operation was contacted and no collaboration between the two companies 
exists.  
 
Literature search 
The literature search was conducted using the keywords BSD-2000 AND hy-
perthermia system. With the limitation to clinical trials, seven hits were pre-
sented.  
 In 1990, a case series including 26 patients was published by 
Sapozink et al. [87].  
 In 1995, Wust et al. reported about a quality control using an animal 
phantom model [88].  
 In 1998 and 2000, Rau et al. published two articles about a case series 
including 37 patients applying the BSD-2000 device [89, 90].  
the device was approved 
under a humanitarian 
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RCT (1996)  
registry study was 
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 In 2004, a case series including 33 patients, in which the BSD-2000 
was applied with a modification to a multi-antenna, was published by 
Wust et al. [91].  
 In 2004, a case series including 28 patients to test the toxicity and the 
feasibility of the hyperthermic chemotherapy approach was published 
by Hildebrandt et al. [92].  
 In 2006, a case series including 41 patients was published by  
Jones et al. [93].  
 In 2006, Sreenivasa et al. reported about a case series including  
32 patients [94].  
 
Clinical trial database  
The database was searched with the keyword BSD-2000 hyperthermia system. 
One clinical trial was registered.  
 The Duke Medical Center reported about a pilot study including 15 
patients concerning the efficacy and safety of hyperthermia in bladder 
cancer treatment in 2008.  
 
Figure 4.5-1: Evidence pyramid for BSD-2000 Microwave Hyperthermia System 
All the evidence available for the BSD-2000 device is summarized in Table 
4.5-1. As the time of CE marking approval is not known, the evidence avail-
able at approval cannot be assessed. For the approval as an HDE by the FDA 
in 2011, one RCT and seven case series were available.  
The evidence presented in the evidence pyramid concludes that the highest 
evidence available is one RCT. A further seven case studies and one on-going 
registry study were found.  
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4.6 Amplatzer™ PFO Occluder 
The following chapter focuses on the Amplatzer™ PFO Occluder. The device 
is manufactured by St. Jude Medical and is currently on the market in Eu-
rope, Australia and Canada. In the United States it was approved under the 
HDE until 2006.  
 
4.6.1 Indication 
The Amplatzer™ PFO Occluder is a patent foramen ovale (PFO) closure de-
vice designed for a minimally invasive transcatheter procedure. A patent fo-
ramen ovale is a tunnel-lie opening between the two upper chambers of the 
heart. This opening is formed during the development of the heart in-utero 
and it generally closes naturally after birth. Yet, in nearly 25% of the general 
population the opening does not close completely. The disease has been re-
lated to paradoxical embolism, orthostatic desaturation, or pulmonary hyper-
tension. It has been investigated whether the administration of a PFO Oc-
cluder may reduce the side effects of the disease [95].  
 
4.6.2 Mechanic procedure 
The Occluder is a double-disc device comprised of nitinol mesh and poly-ester 
fabric. It is designed to close all types of PFOs with an easy-to-perform de-
ployment system. The device is inserted to close the PFO; an optimal fit is 
achieved through a flexible, narrow waist to keep the disc well-opposed to the 
septal walls. The device is inserted through a catheter placed in a vein in the 
groin. The PFO is a permanent implant that stays in the heart after the pro-
cedure [96].  
 
4.6.3 Accessible evidence 
The following section presents the evidence that is publicly available about 
the device. Although the device obtained the CE marking, no information can 
be found as to in which year. In Australia, the device was approved in 2006 
and in Canada in 2001. In the Unites States of America, the device was ap-
proved under HDE until 2006.  
Table 4.6-1: Available evidence for the Amplatzer™ PFO Occluder (extracted on 24.07.2013) 
Studies  
by year 
Level of 
evidence 
FDA  
(no HDE 
since 2006) ARTG TPD 
Notified 
Bodies 
Literature 
Search  
Clinical  
trials 
Kwong, Lam and Yu, 
2013 
Systematic  
literature review  
/ NA NA NA √ - 
Duk-Woo Park 
Research Foundation,  
2012 
Randomized  
clinical trial 
/ NA NA NA - √* 
Stern et al., 2012 Case series / NA NA NA √ - 
Khattab et al., 2011 Randomized  
controlled trial 
/ NA NA NA √ - 
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Studies  
by year 
Level of 
evidence 
FDA  
(no HDE 
since 2006) ARTG TPD 
Notified 
Bodies 
Literature 
Search  
Clinical  
trials  
Fischer et al., 2011 Cohort study / NA NA NA √ - 
Michaels, 2010 Case-control 
study 
/ NA NA NA - √^ 
Taaffe et al., 2008 Randomized  
controlled trial 
/ NA NA NA √ - 
Silvestry et al., 2008 Cohort study / NA NA NA √ - 
AGA Medical  
Cooperation, 2007 
Prospective,  
randomized  
clinical trial 
/ NA NA NA - √* 
AGA Medical  
Cooperation, 2007 
Randomized  
clinical trial 
/ NA NA NA - √* 
AGA Medical  
Cooperation, 2007 
Expanded Access 
– registry study 
/ NA NA NA - √* 
AGA Medical  
Cooperation, 2006 
Randomized  
clinical trial 
/ NA NA NA - √* 
AGA Medical  
Cooperation, 2005 
Randomized  
clinical trial 
/ NA NA NA √ √° 
Salomé et al., 2004 Case series / NA NA NA √ - 
Schwerzmann et al., 
2004 
Case-control 
study 
/ NA NA NA √ - 
Hong et al., 2003 Multicenter  
clinical trial  
(intermediate  
results) 
/ NA NA NA √ - 
Chan et al., 1999 Case series / NA NA NA √ - 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
 
FDA 
The FDA approved the device under the HDE until October, 2006. The de-
cision to withdraw the HDE approval was based on the increasing patient 
numbers treated with the PFO Occluder. Under the HDE, the patient num-
ber per year in the USA may not exceed 4000 patients. However, in 2006 the 
FDA’s review concluded that the patient population significantly exceeded 
4000 patients per year. Therefore, the HDE was withdrawn and the FDA stat-
ed that the device should be subject to the general premarket approval appli-
cation. Up to 2013, the device has not been granted market approval through 
a general authorization pathway [97].  
 
Notified Bodies  
No information was found about the year the CE marking was obtained, the 
Notified Body that granted the CE marking or the evidence submitted.  
 
TGA  
The Amplatzer™ PFO Occluder was found in the ARTG listing; it was ap-
proved in the year 2006. Only the public summary of the ARTG listing can 
be found, but no evidence that has been submitted to support the inclusion 
decision [98].  
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TPD  
The device can be found in the Canadian Device Listing and it was approved 
in 2001. However, the manufacturer of the device is not St. Jude Medical, but 
AGA Medical Corporation. Further research revealed that the two companies 
work in collaboration. The Device Listing does not include any evidence that 
was assessed during the reviewing process and the approval decision [99].  
 
Literature search 
A literature search was conducted with the keywords PFO Occluder AND 
Amplatzer. The search showed ten hits.  
 In 1999, Chan et al. published a prospective, multicenter case study 
including 100 patients [100].  
 In 2003, Hong et al. published intermediate-term results of a US 
multicenter clinical trial. 50 patients were included in this study [101].  
 Schwerzmann et al. published an article about a case-control study in 
2004. The study included 100 patients [95].  
 In 2004, Salomé et al. reported a case series including 27 patients [102].  
 In 2008, a randomized study comparing three PFO Occluder devices 
(Amplatzer, CardioSEAL-STARflex and Helex) was published by 
Taaffe et al. The study included 660 patients [103].  
 In 2008, a long-term follow-up cohort study with 19 cases was 
reported by Silvestry et al. [104].  
 In 2011, a randomized clinical trial with the enrolment of 414 patients 
was published by Khattab et al. [105].  
 In 2011, Fischer et al. published a report about a prospective cohort 
study including 114 patients [106].  
 In 2012, a case series was published by Stern et al. The study 
included 25 patients in total [107].  
 In 2013, a systematic literature review, including a meta-analysis, was 
published by Kwong, Lam and Yu [108].  
 
Clinical trial database  
The clinical trial database was searched with the keywords PFO Occluder 
AND Amplatzer. Seven registered clinical studies were presented.  
 In 2005, the AGA Medical Cooperation initiated a randomized clinical 
trial to assess the safety and effectiveness of the Amplatzer™ PFO Oc-
cluder.  
 In 2006, a randomized clinical trial was sponsored by AGA Medical 
Cooperation to assess the safety and effectiveness of the device in as-
sociation with incidence of headache reduction in subjects with mi-
graines using the PFO Amplatzer™ Occluder.  
 In 2007, AGA Medical Cooperation registered a randomized clinical 
trial to evaluate the recurrence of stroke in patients, comparing the 
PFO closure device to the established current standard of care treat-
ment.  
 In the same year, AGA Medical Cooperation started an expanded ac-
cess study – a registry study.  
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 The PRIMA PFO Migraine Trial, a prospective randomized clinical tri-
al sponsored by the AGA Medical Cooperation, was registered in 2007.  
 In 2010, the University of Utah started a case-control study. 
 In 2012, the Duk-Woo Park Cardiovascular Research Foundation 
from Korea registered a randomized clinical trial within the database.  
 
Figure 4.6-1: Evidence pyramid for Amplatzer™ PFO Occluder 
All the evidence for the Amplatzer™ PFO Occluder has been summarized in 
Table 4-7. No information was found about the year in which the CE mark-
ing was obtained. Therefore, the evidence available at approval cannot be as-
sessed. In 2001, when the device received a license in Canada, one case series 
was available. In 2006, when the FDA withdrew the HDE for the device and 
the device was included in ARTG listing, one case series, one case-control and 
one randomized controlled trial were available.  
All the evidence was put into an evidence pyramid and it can be observed that 
the highest level of evidence, a systematic literature, has been available since 
2013. Further, eight randomized controlled trials, two cohort studies, two case-
control studies, three case series and one case report have been conducted 
over the last years.  
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4.7 MitraClip® 
The following section gives information on the MitraClip®. The device is 
manufactured by the company Abbott and is currently on the market in Eu-
rope, the USA and Australia. The device has just recently been approved 
(March 2013) by the FDA.  
 
4.7.1 Indication 
The MitraClip® is designed to perform a percutaneous mitral valve repair 
(MVR) for the treatment of mitral regurgitation (MR). MR is a mitral valve 
disease and is one of the leading cardiac valve pathologies in Western socie-
ties. MR occurs when the leaflets of the heart’s mitral valve do not close proper-
ly and leak. During the heart’s pumping phase, the leak in the mitral valve 
causes blood to flow into the left atrium and decreases the blood amount that 
is distributed to the body. To maintain regular blood flow and blood distri-
bution into the body, the left ventricle has to increase the pumping activity. 
Eventually this over-activity can cause stroke, irregular heartbeat, progressive 
myocardial injury and congestive heart failure [109].  
 
4.7.2 Mechanic procedure 
The MitraClip® aims at closing the leak in the mitral valve and ensuring 
normal heart functioning. The device consists of a percutaneously delivered 
MRI-compatible, cobalt-chromium implant with two arms and two grippers. 
The procedure is performed under general anesthesia and the device is de-
livered via a transfemoral venous route. Placement of the MitraClip® device 
is supposed to improve the patient condition through advancements in the 
coaptation in the mitral valve leaflet [110].  
 
4.7.3 Accessible evidence 
The subsequent section provides the publicly accessible evidence about the 
device. The device obtained the CE marking in 2008, the ARTG inclusion in 
2010, and the FDA approval just recently in 2013.  
Table 4.7-1:  Available evidence for the MitraClip® 
Studies by  
year Level of evidence FDA ARTG 
TPD (no 
application 
has been 
submitted) 
Notified 
Bodies 
Literature 
Search  
Clinical 
trials  
Munkholm-Larsen 
et al., 2013 
Systematic literature 
review 
- NA / NA √ - 
Evalve, 2013 Randomized clinical trial - NA / NA - √* 
Biner et al., 2012 Case series - NA / NA √ - 
Baldus et al., 2012 Registry study - NA / NA √ - 
Alegria-Barrero  
et al., 2012 
Review –  
State-of-the-Art 
- NA / NA √ - 
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treatment of mitral 
regurgitation through  
a percutaneous mitral 
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Studies by  
year Level of evidence FDA ARTG 
TPD (no 
application 
has been 
submitted) 
Notified 
Bodies 
Literature 
Search  
Clinical 
trials 
Evavle  
(Collaborator  
Abbott Vascular), 
2012 
Clinical Outcome 
Assessment 
- NA / NA - √* 
Auricchio et al., 
2011 
Case series - NA / NA √ - 
Siegel et al., 2011 Case series - NA / NA √ - 
Conradi et al., 2011 Case series - NA / NA √ - 
Franzen et al., 2011 Case series - NA / NA √ - 
Evalve  
(Collaborator  
Abbott), 2011 
Observational cohort 
study 
- NA / NA - √* 
Rudolph et al., 
2011 
Case series - NA / NA √ - 
Evalve, 2011 Observational cohort 
study 
- NA / NA - √* 
Deutsches  
Herzzentrum  
München, 2011 
Randomized clinical trial - NA / NA - √* 
Franzen et al., 
2010 
Case series - NA / NA √ - 
Mieghem et al., 
2010 
Review - NA / NA √ - 
Schaefer and 
Bertram, 2010 
Review - NA / NA √ - 
Herrmann et al., 
2006 
Case series - NA / NA √ - 
REALISM,  
2005 
Prospective access 
registry 
√ NA / NA - - 
High Risk Registry 
(HRR), 2008 
Registry study √ NA / NA - - 
EVEREST I, 2005 Feasibility study √ NA / NA √ √ 
EVEREST II, 2005 Randomized clinical trial √ NA / NA √ √* 
Explanation: * Not completed ° Status unknown ^Terminated/Suspended, cursive – not authorized, underlined – authorized 
 
FDA 
The FDA has just recently approved the premarket application of the Mi-
traClip® device. In March 2013, a panel committee voted on the approval 
with eight out of nine votes in favor of the device. The evidence the FDA has 
based their decision on is subsequently summarized [111]:  
 The EVEREST I trial (2005), a feasibility study that involved 55 patients.  
 The EVEREST II study (2005), a randomized controlled trial included 
279 patients.  
 The High Risk Registry (HRR) was an adjunctive, single-arm registry 
approved by the FDA for conjoined evaluation with the EVEREST II 
study data. The HRR enrolled 78 patients.  
 The REALISM study (2013), currently on-going, aims at data collec-
tion of high-risk patients and the use of the MitraClip® device. The 
study was designed as a prospective access registry. 
recently approved the 
device (March 2013) 
based on 4 studies  
EVEREST I,  
feasibility study (2005)   
EVEREST II, randomized 
controlled trial (2005)   
High Risk Registry 
(2008)  
REALISM, prospective 
access registry –  
on-going (2013) 
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Notified Bodies  
The MitraClip® device was approved for the European market in 2008. In-
formation about the approval process and the evidence used as the basis for 
this approval decision are not publicly available.  
 
TGA   
The device may be legally marketed in Australia since 2010. In the ARTG list-
ing, the device can be found and the public summary of the device is accessible. 
However, no evidence on which the decision was taken can be detected [112].  
 
TPD  
The device is not approved in Canada and no information can be found con-
cerning a possible application or any evidence that has been submitted to the 
Canadian regulatory body.  
 
Literature search 
The literature search using MitraClip® OR mitral regurgitation as the search 
keyword resulted in fourteen hits. 
 In 2006, Herrmann et al. conducted a case series including 27 patients 
[113].  
 Feldman et al. published data in 2009 about safety and mid-term du-
rability assessed in a prospective, multicenter single-arm study. A total 
of 107 patients from the EVEREST I cohort were included in the study 
[114].  
 In 2010, Schaefer and Bertram released a review about the treatment of 
MR with devices such as the MitraClip® [115].  
 In the same year, 2010, another review was published by  
Mieghem et al. [116].  
 Franzen et al. performed a case series with 51 patients in 2010 [117].  
 In 2011, a case series by Rudolph et al. was published.  
104 patients were included in the study [118].  
 Franzen et al. performed a retro perspective analysis in 2011 [119]. 
 A case series with 51 patients was provided by Auricchio et al. in 2011 
[120].  
 Likewise in 2011, Conradi et al. published data about a case series  
including 215 patients [121].  
 Siegel at al. evaluated 107 patients in a case series, published in 2011 
[122].  
 A case series from Biner et al. in 2012 assessed 107 patients and the 
acute procedural success (APS) after the MitraClip® therapy [123].  
 A review of the state-of the art of edge-to-edge percutaneous repair of 
severe mitral regurgitation was published by Alegria-Barrero et al. in 
2012 [124].  
 In 2012, Baldus et al. presented initial results from the German trans-
catheter mitral valve interventions registry study (TRAMI). The study 
enrolled 486 patients into a registry [125].  
 A systematic review was published by Munkholm-Larsen et al. in 2013 
[126].  
no information 
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no premarket approval 
application 
14 publications  
case series (2006) 
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Clinical trial database  
Six studies were found in the clinical trial registry, seven of which were con-
sidered as relevant for this research.  
 In overlap with the evidence the FDA has used for the approval deci-
sion, the EVEREST I feasibility study from 2005 and the EVEREST II 
randomized clinical trial from 2005 were registered within the data-
base.  
 A 2011 randomized clinical trial from the German Heart Centre Mu-
nich was found in the database.  
 In the same year, 2011, Evalve started the ACCESS-Europe study, an 
observational cohort study. 
 In 2011 as well, Evalve, in collaboration with Abbott, initiated another 
observational cohort study for the MitraClip® in Australia and New 
Zealand.  
 Evalve and Abbott Vascular collaborated in starting a clinical outcome 
assessment of the MitraClip® therapy in high-risk surgical patients. 
The trial was first received in 2012. The recruitment phase is current-
ly running.  
 In 2013, Evalve has designed a randomized study for the MitraClip® 
device in heart failure patients with clinically significant functional 
mitral regurgitation. The trial has not started recruitment yet.  
 
Figure 4.7-1: Evidence pyramid for MitraClip® 
EVEREST I and 
EVEREST II (2005) 
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All the evidence for the MitraClip® device is summarized in Table 4.7-1. At 
the CE marking approval in 2008, one case series and one randomized con-
trolled trial were available. In 2010, for the ARTG inclusion, two randomized 
controlled trials, three case series and one review were available. In 2013, when 
the FDA approved the device, five systematic literature reviews, five random-
ized controlled trials, two cohort studies and eight case series were available.  
Summarizing the evidence for the MitraClip® in the evidence pyramid, it can 
be observed that the highest level of evidence available are the systematic lit-
erature reviews. Randomized controlled trials, cohort studies and case series 
are also available.  
 
 
CE marking:  
1 RCT, 1 case series, 
ARTG inclusion: RCTs,  
3 case series, 1 review, 
FDA approval:  
5 SLRs, 5 RCTs,  
cohort and 8 case series  
 
highest level of evidence 
available SLRs  
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5 Reimbursement 
All medical devices generally undergo a standard life-cycle with specified 
pathways. Within this life-cycle, the two most important assessments are the 
authorization evaluation and the reimbursement appraisal of the devices. As 
explained earlier, set regulations exist in different countries for the authori-
zation evaluation of medical devices. Regulatory bodies are set in place, as 
the gateway medical devices have to pass in order to obtain the premarket ap-
proval. However, only being authorized does not implicitly entail the availa-
bility of the device on the market. Subsequently, national funding bodies, in-
surance programs or HTA institutions review medical devices a second time. 
Different national reimbursement frameworks for the assessments of evidence 
of the products in question exist [127]. 
There is a great variety in the way these national reimbursement frameworks 
and their assessment methods are organized. Every system has specific char-
acteristics, which place focus on different evidence requirements. National 
authorities responsible for taking such reimbursement decisions need high-
quality and objective evidence from arduous clinical research to conduct liable 
assessments [128].  
In this chapter, the reimbursement evaluation and/or the guidance provided 
by insurance programs, national funding bodies and national HTA-institutes 
for the seven medical devices is analyzed. Self-explaining only devices that 
have been granted market entry through the authorization process within the 
national evaluation are further considered in this research. As there is a great 
variety of national reimbursement and/or national health technology advising 
institutes, a selection of some institutions has been made in the four selected 
regions (Table 2.4-2).  
Evidence that was used in the reimbursement assessment of the selected in-
stitutes is summarized and analyzed in an evidence pyramid.  
 
 
5.1 United States of America 
In the United States of America, the FDA is the gateway through which new 
drugs and medical devices must pass before they can legally be marketed. 
Yet, the access to the devices, which have been granted market authorization 
by the FDA, is implemented through health insurance programs. That means 
that following the FDA approval, the public or private health insurance pro-
grams will determine whether the approved products are “covered.” The cov-
erage decision can either be a local coverage or a national coverage determi-
nation [129].  
The following section briefly explains the USA healthcare system and its 
characteristics. Subsequently, the MitraClip®, the only device authorized by 
the FDA from the seven exemplary devices, and according documents are 
discussed.  
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5.1.1 The healthcare system  
in the United States of America 
The healthcare system in the United States of America is organized on the 
basis of healthcare insurance programs, either provided by the government 
or privately/by employers. There are several health insurance programs US 
citizens may choose from. What is unique in the system is the strong domi-
nance of the private health insurance programs over the public ones [130].  
The private insurance programs are often associated with the workplace. 
They are also called employer-sponsored insurances. Employers provide 
health insurance as part of the benefit package for employees.  
The insurance programs offered by the government often focus on a certain 
population group, e.g., children or seniors. For the purpose of this research, 
five of the biggest public health insurance programs have been selected: the 
Medicare and Medicaid Services (CMS), Aetna, BlueCross and BlueShield 
Association (BCBS), Healthcare United and Kaiser Permanente.  
Further, the Agency for Healthcare Research and Quality (AHRQ) was cho-
sen for this research. The agency is a national HTA institute frequently pub-
lishing reports about new medical interventions.  
 
Guidance on the medical devices in the United States of America 
The five insurance programs and the national health insurance institute were 
scanned for guidance reports or coverage decision documents. All available 
evidence regarding the coverage or reimbursement for the MitraClip® is sum-
marized in Table 5.1-1.  
Table 5.1-1: MitraClip® recommendations in the United States of America 
Insurance program  Status  
CMS Application for coverage fiscal year 2014  
Aetna  No information available  
BCBS No information available  
Healthcare United  Coverage decision for transcatheter heart valve procedures –  
MitraClip® included 
Kaiser Permanente Guidance for cardiac rehabilitation – Recommendation mitral valve repair 
or replacement 
AHRQ (HTA institute)  Horizon scanning report: MitraClip® device – expected high impact  
 
CMS 
The CMS states that Medicare coverage is limited to items and services that 
are necessary and practical for the diagnosis or treatment of diseases. The 
national coverage decisions (NCDs) from Medicare are an evidence-based pro-
cess with public participation. In the case of rejection for an NCD, Medicare 
has installed local coverage determination (LCD) possibilities. A Medicare 
Evidence Development & Coverage Advisory Committee (MEDCAC) exists 
within the CMS [131].  
The MEDCAC has the responsibility to give expert advice to Medicare for 
coverage decisions. During the decision process, the medical device is classi-
fied into different benefit categories. 55 benefit categories currently exist and 
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to be eligible for coverage under Medicare, the health service in question has 
to fit into these categories. In addition, it is stated that no payment will be 
made for health services that are not necessary or reasonable for the diagno-
sis or treatment of illness or injury [131].  
A coverage database is provided on the official CMS homepage, listing all 
products, pharmaceuticals and medical devices that have been allowed for 
coverage. Currently, only an application for coverage of MitraClip® is pro-
vided [132].  
This can be explained by the fact that the FDA just very recently approved 
the MitraClip® (in March 2013). The coverage database only lists a new tech-
nology add-on-payment application document for the fiscal year 2014. The 
document states that an application for the coverage of the MitraClip® has 
been submitted under the acute inpatient prospective payment system (IPPS).  
No information is available on the evidence that will be used for the cover-
age decision for the MitraClip®. It is expected that more information will be 
accessible through the CMS after the decision for the application is made in 
2014.  
 
Aetna 
On the homepage of the Aetna health insurance program, no information or 
evidence about the device can be found when searching with the keywords 
Mitra Clip® OR mitral regurgitation.  
The Aetna health insurance program consists of various health plans for dif-
ferent population groups. In general, a device is covered if the insurance pro-
gram considers the device “necessary” for the intended indication.  
Coverage decisions are generally available for aortic or pulmonary valve im-
plantation, but not for mitral valve implantation. Nevertheless, the procedure 
for mitral valve replacement surgery is explained in detail by the Aetna health 
expert group [133].  
 
BCBS 
The homepage was searched using the keywords MitraClip® OR mitral re-
gurgitation. No information about the MitraClip® can be found on the Blue-
Cross and BlueShield Association homepage.  
 
Healthcare United 
On the Healthcare United homepage, a medical policy document with cov-
erage decisions about transcatheter heart valve procedures can be found. The 
document provides assistance in interpreting the benefit plan of the insurance 
program. Moreover, the document includes coverage decisions about aortic 
valves, pulmonary valves and mitral valves.  
The document came into effect on July 1, 2013, yet FDA approval informa-
tion from devices was taken as of April 2013. In the document it is stated that 
mitral valves such as the MitraClip® are investigational and unproven de-
vices due to lack of FDA approval [134].  
The evidence to reach this coverage decision is presented in the following:  
 EVEREST I, a multicenter, prospective, single-arm study from 2004.  
 EVEREST II, the two-part multicenter, randomized controlled trial 
from 2005.  
CMS has coverage 
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 EVEREST II, the randomized arm, separate study conducted by 
Feldman et al. in 2011.  
 EVEREST II, the high-risk registry arm, established by  
Whitlow et al. in 2012.  
Further, the document refers to a guidance document created by the National 
Institute for Health and Care Excellence (NICE) from England. This doc-
ument states that the evidence on safety and efficacy for percutaneous mitral 
valve leaflet repair for mitral regurgitation is currently inadequate in quality 
and quantity.  
 
Kaiser Permanente 
On the Kaiser Permanente homepage, a report is available about the recom-
mendations for treatment of mitral regurgitation. The report distinguishes 
between mitral valve repair and replacement. Patient criteria are connected 
to certain recommendations. The MitraClip® device is not explicitly men-
tioned, but the treatment option mitral valve repair with device is recom-
mended for subpopulations [135]. 
 
AHRQ  
In December 2012, the AHRQ published a horizon scanning report about 
emerging medical technologies and the possible impact they will have. The 
MitraClip® was included in the report and considered as a device with an 
expected high impact. It was stated that experts see the unmet patient need 
and that the MitraClip® has the potential to improve patient health.  
Within the report, the following evidence is considered [136]:  
 EVEREST II, randomized controlled trial from 2005  
 Seven expert opinions about the device. 
 
Figure 5.1-1: Evidence pyramid for reimbursement of MitraClip® in the USA  
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From the five insurance programs selected, only one has published a medical 
policy document with associated evidence as the basis for the reimbursement 
decision. The United Healthcare program used four RCTs to reach their cov-
erage decision. Moreover, no information was available from the Aetna and 
the BSBC insurance programs. CMS and Kaiser Permanente provided fiscal 
application, a financial coverage document and a recommendation, but no 
coverage decisions. In addition, the AHRQ considered the device as high im-
pact on the basis of the EVERST II trial and expert opinions given by seven 
professionals.  
It is expected that more information will be available in 2014, as the device 
has just recently approved by the FDA.  
 
 
5.2 Europe 
Within the 28 Member States of the European Union, healthcare has remained 
the responsibility of the separate national healthcare systems. Therefore, a 
great variety of different healthcare systems and reimbursement practices ex-
ists [137]. For the ease of this research, six countries and their associated re-
imbursement or advising HTA institutes were selected (see Table 2.4-2).  
The European authorization system is characterized by the ability to grant 
market authorization to the whole European Single Market, contrary to na-
tional reimbursement practices, which only concern national decisions.  
It is very common in Europe that governmental public health bodies are re-
sponsible for the reimbursement decisions and the implementation of new 
medical devices or services into the healthcare system. Nevertheless, nation-
al HTA advising institutes are often in charge of the evaluation and the as-
sessment of the new medical devices or services. These institutes conduct as-
sessments and provide independent recommendations and guidance to the 
governmental bodies about the reimbursement decision. This research does 
not focus solely on the governmental bodies, but rather on the guidance pro-
vided by the national HTA advising institutes [138].  
Following an overview of the six selected countries and their healthcare sys-
tem, advising HTA institutes are briefly introduced. All seven exemplary med-
ical devices have obtained the CE marking. Consequently, guidance and re-
commendations of the national HTA institutes for all devices, if accessible, 
are provided.  
 
5.2.1 The healthcare system in The Netherlands 
The healthcare system in the Netherlands is based on a combination of a na-
tional health insurance for “exceptional medical expenses,” a social compul-
sory health insurance and private supplementary insurance programs. The 
Ministry of Public Health, Welfare and Sport (VWS) is the key authority for 
health policy. The Ministry, in cooperation with local authorities, is respon-
sible for public healthcare. The system is based on the Exceptional Medicine 
Act (AWBZ) and the Sickness Fund Act (ZFW). In total, there are 22 sickness 
funds that are all regulated by the Healthcare Insurance Board (CVZ). Addi-
tionally, private health insurance programs exist. In cooperation, the VWS 
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and the Sickness Fund Council determine the level of income-related premi-
ums that Dutch citizens would have to contribute. It is important to recognize 
that all budgetary decisions are subject to approval by the Parliament [139].  
The CVZ carries the responsibility of providing the evidence base for the re-
imbursement decisions in The Netherlands. Within the CVZ, a committee 
designated for medical devices will conduct an assessment of the device in 
question. The assessment focuses on the therapeutic effect, which is defined 
by five criteria specified by the CVZ: negative effects, positive effects, expe-
rience with the device, applicability and ease of use. Based on the recommen-
dations of the committee, the CVZ issues an advice to the ministry of health. 
Within the ministry, the final decision is taken as to whether the medical 
device will be allowed for reimbursement by the insurance companies.  
 
Guidance for medical devices in The Netherlands  
In the European Union, all seven exemplary medical devices were authorized 
by the Notified Bodies. The CVZ publishes assessments made on medical 
devices in Dutch and English on their homepage. Following are the results.  
Table 5.2-1: CVZ recommendations 
Medical device Guidance from CVZ 
Zephyr® Endobronchial Valve  No recommendation (2012) 
Paracor Ventricular Support System (PVSS) No assessment available  
Annular repair device Barricaid® No assessment available  
Rheofilter ER-4000 No recommendation (2010) 
BSD-2000 Microwave Hyperthermia System  No recommendation for bladder carcinoma (2006) 
Amplatzer™ PFO Occluder No assessment available  
MitraClip® No assessment available  
 
Zephyr® Endobronchial Valve  
The CVZ has assessed the endobronchial lung volume reduction therapy for 
emphysema. It is stated that this therapy, based on the current literature, can-
not be seen as clinically effective with an added therapeutic value for the pa-
tient. Therefore, the recommendation on the therapy including the Zephyr® 
Endobronchial Valve is negative and the CVZ advises to not allow reimburse-
ment. Further, it is recognized that there might be subpopulations that benefit 
from the therapy and that current research for those groups is being conduct-
ed. The guidance was published on December 21, 2012 [140].  
The following evidence was considered within the reimbursement decision:  
 19 patients were included in the case study published by  
de Oliveria in 2006 [141].  
 Springmeyer et al. published a case series with 98 patients from  
2009 [142].  
 A randomized controlled trial from Sciurba et al. in 2010 [65].  
 A pilot study from Sterman et al., inclusion of 91 patients in the year 
2010 [143].  
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 Kotecha et al. conducted a retrospective cohort study in 2010  
including 23 patients [144].  
 Case series from Venuta et al. from 2011 – 40 patients included [145].  
 One double-blinded sham controlled randomized controlled trial 
conducted from Ninane et al. in 2012 [146].  
 Randomized controlled trial from Herth et al., published in 2012 [66].  
 
Figure 5.2-1: Evidence pyramid reimbursement Zephyr® in The Netherlands 
The Zephyr® device was assessed on the basis of three randomized controlled 
trials, one cohort study and four case series. The device was not seen as safe 
and effective by the CVZ. The device was rejected from reimbursement in the 
year 2012.  
 
Paracor Ventricular Support System (PVSS) 
No assessment for the PVSS could be found on the CVZ homepage. It can be 
assumed that the device has not been assessed and is therefore not subject to 
reimbursement in The Netherlands.  
 
Annular repair device Barricaid® 
No assessment for the annular repair device could be found on the CVZ home-
page. It can be assumed that the device has not been assessed and is therefore 
not subject to reimbursement in The Netherlands. 
 
Rheofilter ER-4000 
The CVZ has published guidance about the Rheopheresis therapy for dry 
AMD. On the basis of a systematic literature review focusing on the effec-
tiveness of the therapy, the CVZ has concluded that no acceptable evidence 
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exists to support the effectiveness of the Rheopheresis therapy. In the guid-
ance, the CVZ outlines that there are questions about the rationale of this 
therapy, that there are no guidelines standardizing the therapy and that many 
other countries do not reimburse and cover the therapy. Therefore, the CVZ 
summarizes that Rheopheresis should not be provided in The Netherlands, 
as the therapy is not confirmed by sound scientific studies. The guidance of 
published on October 5, 2010 [147].  
The CVZ considered the following evidence in its evaluation:  
 A randomized controlled trial, the MAC-1, published by  
Brunner et al. in 2000 [148].  
 A systematic literature review published by Wild et al. in 2009 [81].  
 The ART-trial, a randomized trial published in 2009 by Koss et al. [83].  
 Randomized controlled trial by Rencova et al. from 2010 [149].  
 
Figure 5.2-2: Evidence pyramid reimbursement Rheofilter ER-4000 in The Netherlands  
The Rheofilter ER-4000 was assessed by the CVZ considering one systematic 
literature review and three randomized controlled trials. On the basis of the 
available evidence, reimbursement cannot be approved by the CVZ.  
 
BSD-2000 Microwave Hyperthermia System  
The published guidance from June 24, 2011 focuses on the combination ther-
apy of hyperthermia and chemotherapy for bladder carcinoma. The CVZ con-
cludes that this therapy cannot be considered a therapy conforming with the 
scientific standards. Reimbursement is not advised [150].  
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In the evaluation report the following evidence is included:  
 In 1998, Colombo et al. published another case series [151].  
 A guidance report from NICE about hyperthermia from 2007 [152]. 
The NICE SR included the following clinical trials:  
 Gofrit et al. published a case series in 2004 [153].  
 In 2004, another case series was published by  
van der Heijden et al. [154].  
 In 2003, a randomized controlled trial was published by  
Colombo et al. [155].  
 In 2001, a comparative study was published by Colombo et al. [156].  
 Colombo et al. published a randomized controlled trial in 1996 [157].  
 In 1995, Colombo et al. published an article about a case series [158]. 
 In the same year, 2011, another case series was published by  
Nativ et al. [159].  
 Witjes et al. published a case series in 2009 [160]. 
 In 2011, a randomized controlled trial was conducted by  
Colombo et al. [161].  
 
Figure 5.2-3: Evidence pyramid reimbursement BSD-2000 in The Netherlands 
The CVZ considered all the evidence from a SR from the NICE and con-
ducted an additional literature search. In total, the reimbursement decision 
is based on three randomized controlled trials and seven case series. The ev-
idence from all these studies is not enough to support the hyperthermia treat-
ment for reimbursement limited to the indication of bladder carcinoma.  
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Amplatzer™ PFO Occluder 
No assessment for the Amplatzer™ PFO Occluder System could be found on 
the CVZ homepage. It can be assumed that the device has not been assessed 
and is therefore not subject to reimbursement in The Netherlands. 
 
MitraClip® 
No assessment for the MitraClip® could be found on the CVZ homepage. It 
can be assumed that the device has not been assessed and is therefore not sub-
ject to reimbursement in The Netherlands. 
From the seven authorized high-risk medical devices, three have been subject 
to negative guidance and were not recommended for reimbursement by the 
CVZ. The other four have not yet been assessed.  
 
5.2.2 The healthcare system in Germany 
The Statutory Health Insurance Funds (SHIs) are responsible for the costs 
of healthcare delivery to their insured members. Private health insurance ex-
ists and can be used for extra services or if the income of the insured mem-
ber exceeds a certain threshold.  
Medical devices are used in inpatient and ambulatory settings, and the reim-
bursement and funding mechanisms for the both settings are different. It can 
be recognized that all medical devices and diagnostics are subject to contracts, 
yet these contracts differ between the inpatient and ambulatory setting.  
The inpatient sector mechanism is regulated by the “hospital funding act.” 
The principle mechanism of the reimbursement by the SHIs is based on a 
prospective payment system (PPS), also called the German Diagnosis Relat-
ed Group (DRG). The ambulatory setting is served by physicians that are paid 
in accordance with the EBM (Einheitlicher Bemessungsmassstab), which in-
cludes a mix of services delivered, number of patients served and a fixed 
budget distribution system. 
Three institutes are responsible for the pre-reimbursement assessments and 
coverage decisions: The G-BA, (Gemeinsamer Bundesausschuss – Federal 
Joint Committee) is the main governmental body responsible for taking de-
cisions about reimbursement of pharmaceuticals and medical devices. It is the 
highest decision-making body of the joint self-government of health insur-
ance funds, hospitals, physicians and dentists in Germany. The G-BA con-
ducts and performs assessments of new medical devices or services and issues 
directives for the benefit catalogue of the statutory health insurance funds. 
Through these directives, the G-BA specifies which medical services are re-
imbursed by the statutory health insurance funds. However, some assessments 
are forwarded to the second selected institute, the IQWIG (the Institute for 
Quality and Efficiency in Healthcare). The IQWIG is an independent HTA 
institute assessing medical technologies and giving recommendations about 
their characteristics. The third body, the MDS, is an umbrella organization 
of German sickness funds; the MDS assessments are not publicly available.  
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Guidance on the medical devices in Germany 
In the European Union, all seven exemplary medical devices were authorized 
by the Notified Bodies. The G-BA, the IQWIG and the MDS were searched 
for assessments and published guidance. The reimbursement decisions are 
provided in German or English.  
Table 5.2-2: G-BA, IGWIQ and MDS recommendations 
Medical device 
Guidance  
from G-BA 
Guidance  
from IQWIG 
Guidance  
from MDS 
Zephyr®  
Endobronchial Valve  
Report about 
therapies for COPD 
Guidelines for the 
treatment of COPD 
No information 
available 
Paracor Ventricular  
Support System (PVSS) 
No assessment  No assessment  No assessment  
Annular repair device 
Barricaid® 
No assessment  No assessment  No assessment  
Rheofilter ER-4000 No recommendation 
(2003) 
No assessment  No assessment  
BSD-2000 Microwave 
Hyperthermia System 
No recommendation 
(2005) 
No assessment  No assessment  
Amplatzer™ PFO Occluder No assessment  No assessment  No assessment  
MitraClip® No assessment  No assessment  No recommendation 
(2012) 
 
Zephyr® Endobronchial Valve 
The G-BA published a decision about therapies for COPD. Within this deci-
sion, it is stated that operative procedures for the treatment of emphysema 
should be used with caution. The Zephyr® device is not explicitly mentioned. 
The decision is dated September 21, 2004 [162].  
The IQWIG recently published a preliminary report with guidelines for the 
treatment of COPD on May 8, 2013. However, the treatment with any endo-
bronchial valve and its assessment were not included [163].  
No assessment was available from the MDS.  
The manufacturer has provided a complete literature list and explanation of 
how to access treatment with the endobronchial valve. The treatment can be 
organized by contacting the manufacturer.  
 
Paracor Ventricular Support System (PVSS) 
No assessment for the Paracor Ventricular Support System could be found 
within the G-BA, IQWIG or MDS databases. It can be assumed that the de-
vice has not been assessed and is therefore not subject to reimbursement in 
Germany. 
 
Annular repair device Barricaid® 
No assessment for the annular repair device Barricaid® could be found within 
the G-BA, IQWIG or MDS databases. It can be assumed that the device has 
not been assessed and is therefore not subject to reimbursement in Germany. 
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Rheofilter ER-4000 
For the treatment of AMD with Rheopheresis, a 2003 evaluation report by the 
G-BA is available. A broad range of indications for Rheopheresis treatment 
are discussed in the report. In addition, the report states that currently the 
Rheopheresis treatment cannot be advised for inclusion into the standard of 
care [164].  
The evidence considered within the report is summarized as follows:  
 In 1999, an article about a prospective randomized controlled trial was 
published by Swartz and Rabetoy [165].  
 Brunner et al. published a prospective randomized controlled trial in 
2000 [148].  
 A summary of the MIRA-I randomized trial presented at a conference 
in 2011 [166].  
No assessment for the Rheofilter ER-4000 could be found within the IQWIG 
or MDS databases.  
 
Figure 5.2-4: Evidence pyramid reimbursement Rheofilter ER-4000 Germany 
The G-BA has assessed the Rheopheresis treatment for AMD based on two 
randomized controlled trials and one summary of an on-going trial. With this 
evidence as basis, the treatment is not recommended for reimbursement.  
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BSD-2000 Microwave Hyperthermia System  
The G-BA published an evaluation report about whole-body or partly hyper-
thermia treatment in 2005. The report focuses on different indications for 
the treatment, concluding that currently hyperthermia should only be used 
under investigational circumstances with caution [167].  
The evidence used for this report is indication-specific, but special attention 
was paid to cervical cancer and the treatment with hyperthermia. Five pri-
mary studies were evaluated in more depth for the report:  
 A prospective randomized study published by  
Sharma et al. in 1990 [168].  
 A randomized controlled trial as well from  
Sharma et al. in 1991 [169].  
 Case series by Gupta et al. from 1999. Included were 69 patients [170].  
 A randomized controlled trial published in 2001 by Harima et al. [171]. 
 Van der Zee and Gonzales reported about the Dutch Deep Hyper-
thermia Trial, a multicenter, randomized clinical trial in 2002 [172].  
 
Figure 5.2-5: Evidence pyramid reimbursement BSD-2000 Microwave Hyperthermia  
System Germany 
The G-BA published a report concluding that hyperthermia cannot be reim-
bursed on the basis of the available evidence. The decision was taken with 
primary focus on four randomized controlled trials and one case series.  
 
Amplatzer™ PFO Occluder 
No assessment for the Amplatzer™ PFO Occluder could be found within the 
G-BA, IQWIG or MDS databases. It can be assumed that the device has not 
been assessed and is therefore not subject to reimbursement in Germany. 
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MitraClip® 
Within the MDS database, a summary of newly evaluated medical technolo-
gies includes the assessment of the MitraClip®. After assessing the device, 
the summary states that the device is currently not recommended for reim-
bursement, as no clear beneficial therapeutic value can be identified. The 
assessments summary was published in August 2012. The assessment was 
carried out in collaboration with the LBI-HTA.  
No assessment for the MitraClip® could be found within the G-BA and IQWIG 
databases. It can be assumed that the device has not been assessed and is 
therefore not subject to reimbursement in Germany. 
From all seven medical devices that have been approved by the accredited 
Notified Bodies, three have received negative recommendations for the re-
imbursement. Four devices have not been assessed so far.  
 
5.2.3 The healthcare system in England 
In England, the healthcare system is based on the National Health Service 
(NHS). The NHS is funded by taxes and NHS coverage for health services is 
comprehensive and, in most cases, free of charge. The Secretary of State of 
Health is responsible for the provision of health services within the NHS. Fur-
ther, the NHS is divided into ten so-called strategic health authorities (SHA). 
The SHAs are in charge of supervising the NHS trusts in their respective areas.  
The central advising body to the NHS is the National Institute for Health and 
Care Excellence (NICE). The department of the Medical Technologies Ad-
visory Committee (MTAC) is the main body responsible for medical devices 
within the NICE. The main criteria the NICE uses for the assessment of a 
product are clinical evidence and economic evidence. Each assessment can 
lead to recommendations that are classified in four categories: recommended, 
optimized, only in research or not recommended. A specified program for 
medical technologies and their evaluation exits. This program, the “Medical 
Technologies Evaluation Programme,” selects and evaluates new or innova-
tive medical technologies to help the NHS adopt efficient and cost effective 
medical devices more rapidly and consistently.  
 
Guidance on the medical devices in England  
All seven devices were granted the CE marking for Europe. The NICE was 
searched for guidance reports available for the devices.  
Table 5.2-3: NICE recommendations 
Medical device Guidance from the NICE 
Zephyr® Endobronchial Valve  No recommendation (2013)  
Paracor Ventricular Support System (PVSS) No assessment available  
Annular repair device Barricaid® Assessment in progress (2013) 
Rheofilter ER-4000 Not used within NHS care (2010) 
BSD-2000 Microwave Hyperthermia System  Only for use in clinical settings (2007)  
Amplatzer™ PFO Occluder No safety concerns – efficacy not proven (2005)  
MitraClip® Not recommended for reimbursement (2009) 
MitraClip® not 
recommended for 
reimbursement  
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recommended for 
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Zephyr® Endobronchial Valve  
Guidance and recommendations for the usage of the therapy with endobron-
chial valves were found on the NICE homepage. The NICE states that current 
evidence on the efficacy and safety of insertion of endobronchial valves for 
persistent air leaks is limited in both quantity and quality. Therefore, this pro-
cedure should only be used with special arrangements for clinical governance, 
consent and audit, or research. The guidance is from September 2013 [173].  
Evidence that was used within the report is as follows:  
 Sternman et al. published about a case series in 2010 [143].  
 A randomized controlled trial by Sciurba et al. in 2010 [65]. 
 Case series by Venuta et al. in 2011 included 98 patients [62]. 
 Hopkinson et al. reported about a case series including 19 patients  
in 2011 [174]. 
 Herth et al. reported about a randomized controlled trial in 2012 [66].  
 Another randomized controlled trial by Ninane et al. in 2012 [146].  
 Herth et al. published a case series including 96 patients in 2012 [175].  
 
Figure 5.2-6: Evidence pyramid reimbursement Zephyr England 
The decision from the NICE was based on four randomized controlled trials 
and one case series. The evidence presented within those five articles was not 
enough to support reimbursement.  
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Many different assessments were presented on the NICE homepage for car-
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Annular repair device Barricaid® 
It is stated on the NICE homepage that the Institute has been informed about 
the annular disc implant lumbar discectomy procedure and the guidance re-
port is in progress. NICE is still waiting for further publications on this topic.  
 
Rheofilter ER-4000 
NICE stated that the Rheopheresis treatment is not used within the NHS care. 
The treatment is limited to official UK research centres. The notice is from 
March 30, 2010.  
 
BSD-2000 Microwave Hyperthermia System  
The NICE published a guidance report in 2007 about the treatment of blad-
der cancer with microwave hyperthermia and chemotherapy. It concluded that 
the treatment should only be used in clinical trial settings, since evidence is 
very limited [176].  
Evidence that was used in the report:  
 A case series by Colombo et al. in 1995 [158].  
 A randomized controlled trial by Colombo et al. from 1996 [157]. 
 In 2001, a non-randomized controlled trial by Colombo et al. [156].  
 A randomized controlled trial in 2003 by Colombo et al. [155]. 
 Case series by Gofrit et al. in 2004 [153].  
 
Figure 5.2-7: Evidence pyramid reimbursement BSD-2000 Microwave Hyperthermia  
System England 
The NICE considered two randomized controlled trials, one case-control study 
and two case series for the guidance report about hyperthermia treatment for 
bladder cancer. The NICE reached the decision that the treatment should 
only be used within clinical trial settings.  
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Amplatzer™ PFO Occluder 
A guidance report from January 2005 by NICE for the percutaneous closure 
of patent foramen ovale for the prevention of cerebral embolic stroke states 
that current evidence suggests that there are no major safety concerns and that 
percutaneous closure of patent foramen ovale for the prevention of cerebral 
embolic stroke is efficacious in achieving closure of the foramen. However, 
its efficacy in preventing future strokes has not been clearly shown [177].  
Evidence sources used for the guidance document are not accessible – it is 
stated on the NICE homepage that the requested document is currently not 
available and that it was last updated on February 8, 2011.  
 
MitraClip® 
The NICE issued a guidance report on percutaneous mitral valve leaflet re-
pair for mitral regurgitation in August 2009. The report states that evidence 
on the safety and efficacy of the procedure is currently inadequate in quantity 
and quality. It is explained that the procedure should only be used with spe-
cial arrangements and in the context of clinical research [178].  
Evidence that was used in the guidance report is:  
 Dang et al. reported about a case series in 2005 with six patients  
included [179].  
 A phase I trial including 27 patients by Feldman et al. in 2005 [180].  
 Herrmann et al. published an article about a phase I trial in 2006  
including 27 patients [113] 
 A case study was presented by Condado et al. in 2006, looking at one 
patient [181].  
 A multicenter case series from 2008 published by Silvestry et al. [104].  
 
Figure 5.2-8: Evidence pyramid reimbursement MitraClip® England 
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NICE based the guidance report on two case series and two phase I trials. 
The Institute considered the evidence as inadequate and the procedure was 
therefore not recommended.  
 
5.2.4 The healthcare system in Austria 
The Statutory Health Insurance Funds (SHIs) are responsible for the costs 
of healthcare delivery to their insured members. Private health insurance ex-
ists and can be used for extra services or if the income of the insured member 
exceeds a certain threshold.  
The system is highly decentralized with the Ministry of Health formulating 
the policy framework and the nine federal states managing the healthcare 
delivery. The main association of the Austrian Social Security Institutions 
(Hauptverband der österreichischen Sozialversicherungsträger) and the as-
sociated 19 sickness funds ensure the implementation of this social insurance 
system. In general, healthcare contributions are based on the income of the 
insured person, with exemptions made for low-income and severely ill indi-
viduals. There are three different benefit catalogues (for drugs, for ambulatory 
care and for hospital interventions).  
The Ludwig Boltzmann Institute for Health Technology Assessment (an in-
dependent academic institute) is contracted by the Ministry of Health to eval-
uate medical interventions delivered in hospitals. The institute focuses on 
clinical effectiveness and safety.  
 
Guidance on the medical devices in Austria 
In the European Union, all seven devices have been granted CE marking. In 
the following, the evidence from guidance reports for Austria for the seven 
devices is summarized.  
Table 5.2-4: LBI-HTA recommendations  
Medical device Guidance from the LBI  
Zephyr® Endobronchial Valve  No recommendation (2010) 
Paracor Ventricular Support System (PVSS) No information available 
Annular repair device Barricaid® No recommendation (2013) 
Rheofilter ER-4000 No recommendation (2008)  
BSD-2000 Microwave Hyperthermia System  No recommendation (2012) 
Amplatzer™ PFO Occluder No assessment  
MitraClip® No recommendation (2012) 
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Zephyr® Endobronchial Valve  
The LBI-HTA published a decision support report in February 2010 about the 
endobronchial valve implementation for COPD. This report states that it is not 
recommended to reimburse the procedure with the valve. Available evidence 
could not prove whether there is a therapeutic benefit for the patient [182].  
The report considered the following evidence in its recommendation:  
 Toma et al. published a case series in 2003 including eight patients [183]. 
 In the same year, 2003, Sabanathan et al. likewise published a case 
series with eight patients [184].  
 Snell et al. reported about a case series including ten patients in 2003 
[185].  
 In 2004, a case series was published by Yim et al.  
including 21 patients [186].  
 In 2005, Venuta et al. published an article about a case series  
including 13 patients [187].  
 In the same year, 2005, Hopkinson et al. reported about a case series 
including 19 patients [61].  
 In 2006, de Oliveira et al. published a case series  
including 19 patients [141].  
 Wan et al. included 98 patients in a case series in 2006 [62].  
 In 2007, Wood et al. reported about a case series  
including 30 patients [188].  
 The randomized controlled trial VENT from 2010.  
 
Figure 5.2-9: Evidence pyramid reimbursement Zephyr® Endobronchial Valve Austria 
The recommendation by the LBI-HTA is based on one randomized controlled 
trial and eight case series. It is currently not recommended to reimburse the 
device in Austria, as the available evidence is not strong enough.  
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Paracor Ventricular Support System (PVSS) 
No assessment for the PVSS could be found within the LBI-HTA decision 
support documents. It can be assumed that the device has not been assessed 
and is therefore not subject to reimbursement in Austria. 
 
Annular repair device Barricaid® 
The LBI-HTA recently published a decision support document in March 2013 
about the therapy with the Barricaid® device. The report states that current 
evidence cannot ensure the safety and effectiveness of the procedure and, 
therefore, the reimbursement recommendation is negative [189].  
Evidence considered within the report is as follows:  
 Multicenter prospective case series by Lequin et al. in 2012 [75]. 
 Case series from Intrinsic Therapeutics – a Clinical Evaluation Report 
including 30 patients from 2012.  
 Ten conference abstracts focusing on the two studies.  
 
Figure 5.2-10: Evidence pyramid reimbursement Barricaid® Austria 
The report from the LBI-HTA considers two case series as the basis for the 
recommendation. It is currently not advised to reimburse the device, but a 
re-evaluation in four years (2017) is recommended as two more clinical trials 
are still on-going.  
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Rheofilter ER-4000 
In March 2008, a decision support document by the LBI-HTA stated that it 
is not recommended to reimburse the Rheopheresis procedure. The current 
evidence is not enough to ensure a therapeutic benefit for patients [190].  
The evidence included in the report is listed below:  
 Brunner et al. published an article about a randomized controlled  
trial in 2000 [148].  
 Interim results published by Pulido in 2002 from the MIRA-I trial.  
 Klingel et al. published a prospective open label trial in 2003 [79]. 
 The RheoNetRegistry report from Klingel et al. in 2005 [82]. 
 Pulido et al. published preliminary results of the MIRA-I trial in 
2006 [80]. 
 
Figure 5.2-11: Evidence pyramid reimbursement Rheofilter-ER 4000 in Austria 
The negative decision is based on two randomized controlled trials, from one 
of which only interim results were available, and on one case series and one 
registry study. It is currently not advised to reimburse the procedure.  
 
BSD-2000 Microwave Hyperthermia System  
Two decision support documents were published by the LBI-HTA, both fo-
cusing on the hyperthermia procedure. The first document, from March 2010, 
recommended not to reimburse the procedure for several cancer indications. 
The second document from December 2012 confirmed the first report by 
stating that current evidence is insufficient to make a judgment about the 
procedure’s clinical benefit and possible associated risks.  
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The evidence that was used in the latter report from 2012 splits the studies 
included over four indications, namely breast cancer, bladder cancer, cervix 
cancer, and soft tissue sarcoma. All studies are presented in the following 
[191]:  
 A randomized controlled trial from Sharma et al. in 1989.  
 A randomized controlled trial for breast tumors from 1991,  
published by Perez et al. [192].  
 A randomized controlled trial from Colombo et al. in 1996 [157].  
 A randomized controlled trial from Vernon et al. published in 1996 
[193].  
 A randomized controlled trial from 2001 by Harima [171].  
 Van der Zee et al. published a randomized controlled trial in 2002 [172].  
 Published by Colombo et al. in 2003, a randomized controlled trial. 
[155].  
 In 2005, a randomized controlled trial from Vasanthan et al. [194].  
 A long-term follow-up by Franckena et al. in 2008 [195].  
 A randomized controlled trial published by Issel et al. in 2010 [196]. 
 A long-term follow-up by Colombo et al. from 2011 [161].  
 
Figure 5.2-12: Evidence pyramid reimbursement BSD-2000 Austria  
The (repeated) recommendation to not reimburse hyperthermia treatment 
was based on nine randomized controlled trials and two long-term follow-up 
studies. The LBI-HTA states that the evidence available for the therapy is 
insufficient to make a judgment on its clinical benefit because of the lack of 
patient-relevant endpoints (rather than surrogate endpoints) and associated 
risks.  
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Amplatzer™ PFO Occluder 
No assessment for the Amplatzer™ PFO Occluder could be found within the 
LBI-HTA decision support documents. It can be assumed that the device has 
not been assessed and is therefore not subject to reimbursement in Austria. 
 
MitraClip® 
The MitraClip® was assessed several times (2010, 2012). The updated report 
concludes that the reimbursement procedure is currently not recommended. 
The decision is based on insufficient evidence to ensure the efficacy and safety 
of the procedure [197].  
The evidence used in the report is as follows:  
 EVEREST I – randomized controlled trial from 2005.  
 A prospective case series published in 2009 by Feldman et al. [114].  
 A randomized controlled trial from 2011 published by Feldman et al. 
– EVEREST II.  
 
Figure 5.2-13: Evidence pyramid reimbursement MitraClip® Austria  
The report from the LBI-HTA bases its decision on one randomized con-
trolled trial and on one case series. The conclusion states that it is currently 
not advised to reimburse the MitraClip®.  
From the seven authorized medical devices, five have been assessed by the 
LBI-HTA and not recommended for reimbursement. No assessment is avail-
able for two devices.  
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5.3 Australia 
In Australia, the federal government is known as the Commonwealth Govern-
ment. The Australian Government Department for Health and Ageing is a 
nationwide body that strives to implement uniform regulations in the health-
care sector.  
The following chapter introduces the Australian healthcare system and its 
main features. In addition, the guidance by the Australian Medicare depart-
ment for the four authorized devices is presented.  
 
5.3.1 The healthcare system in Australia 
The responsibility for healthcare is divided between the federal and the state 
governments. Yet, Australia ensures its healthcare provision through a large 
uniform coverage system – Medicare. Medicare is funded through general tax-
ation and includes all hospital and medical services in its coverage scheme. 
The unique character of Medicare is that it is a governmental coverage sys-
tem. Medicare is organized within the Department of Human Services.  
The Medical Services Advisory Committee (MSAC) is the main body support-
ing Medicare in its reimbursement decisions. The Australian Government 
Health Minister has appointed the MSAC to strengthen the role of evidence 
in health financing decisions in Australia. The main evidence the MSAC fo-
cuses on during their assessments is safety, effectiveness, cost-effectiveness 
and budgetary impact.  
 
Guidance on the medical devices in Australia 
Table 5.3-1: MSAC recommendations 
Medical device  Recommendation MSAC 
Zephyr® Endobronchial Valve  Not supported for public funding (2001)  
Annular repair device Barricaid® No assessment available  
Amplatzer™ PFO Occluder Consultation still on-going (2013)  
MitraClip® Not supported for public funding (2012) 
 
Zephyr® Endobronchial Valve  
The MSAC published a final decision report on lung volume reduction sur-
gery in February 2001. In this report it was stated that the committee does 
not support public funding of the procedure. In April 2001, this recommen-
dation was adopted by the ministry [198].  
The following evidence was used in the assessment:  
 Retrospective analysis of emphysema patients published by  
Licker et al. in 1998 [199].  
 A randomized study by Geddes et al. from 2000 [200].  
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Figure 5.3-1: Evidence pyramid reimbursement Zephyr Australia 
The MSAC based its recommendation on two studies – a randomized controlled 
trial and a retrospective analysis. Based on this evidence, public funding was 
not supported in 2001.  
 
Annular repair device Barricaid® 
No assessment for the annular repair device Barricaid® could be found in the 
MSAC database. It can be assumed that the device has not been assessed and 
is therefore not subject to reimbursement in Australia. 
 
Amplatzer™ PFO Occluder 
The MSAC has published a consultation report and a final decision report 
about the application and the assessment of transcatheter closure of patent 
ductus arteriosus. A decision analytic protocol is attached to guide the further 
assessment of the procedure. Yet, it cannot be gathered from the report wheth-
er the MSAC assessment has been concluded or is still on-going. Therefore, 
no statements can be made about the reimbursement recommendation. The 
report was published in April 2013.  
 
MitraClip® 
The MSAC has provided a public summary document about the MitraClip® 
device and its application for funding. The document is from November 2012. 
The MSAC advises the Ministry that, considering the strength of the availa-
ble evidence, the public funding is not supported by the committee [201].  
The evidence used within the document is:  
 A randomized controlled (EVEREST II) trial by  
Glower et al. in 2011 [202].  
 The EVEREST I data published by Whitlow et al. in 201 [203].  
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Figure 5.3-2: Evidence pyramid reimbursement MitraClip® Australia 
The MSAC based its decision for a negative recommendation for reimburse-
ment on two available randomized controlled trials.  
Four medical devices have been authorized by the TGA and included into the 
ARTG. Of the four devices, three have been assessed by the MSAC. Public 
funding was not supported for two devices. Consultation is still on-going for 
one device.  
 
 
5.4 Canada 
Canada’s healthcare system is fairly different from its neighbor country, the 
United States of America. The TPD, a department within Health Canada, is 
responsible for the authorization of devices, followed by the CAHR/Canadian 
Association of Healthcare Reimbursement, where the reimbursement evalu-
ation takes place.  
In the following chapter, the healthcare system of Canada is briefly outlined 
and the guidance given by the CAHR for the one medical device that has been 
authorized by the TPD is provided.  
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5.4.1 The healthcare system in Canada 
The Canadian healthcare system has a single-payer and mostly publicly fund-
ed basis. The system tries to ensure healthcare access for all Canadian citizens. 
Various social health insurance plans exist that provide coverage for medical 
items and services. The system is responsible for the administration and is 
divided on a provincial or territorial basis, with an obligation to adhere to 
guidelines from the federal government. Under the social health insurance 
plans, citizens are entitled to ambulatory and hospital care. All citizens qualify 
for coverage and no distinctions are made regarding medical history, personal 
income or standard of living.  
The CAHR is an institute comprised of members from academia, industry, 
patient advocacy groups and the government. The association aims at provid-
ing a recommendation about the reimbursement for pharmaceuticals and 
medical devices within the Canadian system.  
 
Guidance on the medical devices in Canada 
Table 5.4-1: CAHR recommendation  
Medical device  Guidance by the CAHR 
Amplatzer™ PFO Occluder No assessment available  
 
Amplatzer™ PFO Occluder 
No assessment for the Amplatzer™ PFO Occluder could be found in the CAHR 
search function. It can be assumed that the device has not been assessed and 
is therefore not subject to reimbursement in Canada. 
 
 
 
 
social health insurance 
plans provide coverage 
for all citizens  
CAHR provides 
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6 Discussion 
This research had two main objectives: Firstly, to explore and explain the 
authorization (premarket approval) systems for medical devices and their re-
spective requirements for clinical evidence in the four selected regions, namely 
Europe, the United States of America, Canada and Australia. Secondly, to 
analyze the level of evidence (along the commonly used hierarchy of evidence) 
used for authorization and reimbursement decisions. As examples, seven high-
risk medical devices were selected.  
The research has several limitations that have to be recognized. It has been 
decided to only include high-risk medical devices into this research, because 
they are the ones most often in the focus of a new regulation of market ap-
proval in Europe. There are hundreds of high-risk devices on the markets, and 
to concentrate on a few only gives a limited, hardly generalizable picture. In 
addition, only the four selected regions are being considered, because for the 
time being they represent the most important markets for high-tech medical 
interventions. Though the Asian and Latin American markets for medical 
devices are growing fast, their premarket approval systems have not been ana-
lyzed. Finally, only seven medical devices have been chosen as an exemplary 
basis for detailed analysis. 
The information provided here is therefore not generalizable and only appli-
cable for the four regions and for a small scope of medical devices. Within the 
four regions, data collection was limited to accredited regulatory bodies for 
authorization and for national reimbursement decisions. Only information 
that was publicly accessible was included. For all these reasons, the informa-
tion presented is far from being comprehensive. 
 
Authorization  
All seven exemplary medical devices have been approved in the European 
Union through an appointed Notified Body (not known). Four obtained ap-
proval by the Australian TGA/Therapeutic Goods Administration (MitraClip®, 
Amplatzer, Barricaid, Zephyr) and only one each by the US-American FDA 
(MitraClip®) and by the Canadian TPD/Therapeutics Products Directorate 
(Amplatzer) (Figure 6-1).  
 
Figure 6-1: Approval of seven selected devices in USA, Europe, Canada, Australia 
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In comparison to the other three regulatory systems, the number of approved 
devices in Europe is strikingly high, especially if additionally considering that 
four further devices were also assessed by the FDA, but not approved: Two 
did not obtain approval (Zephyr and PVSS), two received only HDE exemp-
tions (in research only: Hyperthermia and Amplatzer), of which one HDE 
exemption was withdrawn because of an exceeding number of patients per 
year. A premarket approval is pending. 
In almost all of the analyzed seven examples, the premarket approval in Eu-
rope was granted two to five years before authorization in other systems. The 
evidence used for CE marking is not known in all exemplary devices, due to 
the highly decentralized authorization system and the lack of transparency 
of the respective Notified Body that issued CE marking. Even if the clinical 
evidence used is not known, it is naturally less mature (case studies or non-
comparative case series only, interim analysis of RCTs) than later premarket 
approvals. 
Table 6-1: Overview on available evidence for authorization  
and reimbursement and of recommendations for seven devices in Europe, USA, Canada, Australia 
Medical Device 
Authorization:  
year, evidence 
Reimbursement:  
year, evidence, recommendation 
Zephyr® 
Endobronchial Valve  
  
Europe 2003 (approval),  
no information 
Netherlands (CVZ): 2012, RCT, not recommended 
Germany (G-BA, IQWIG, MDS): 2004 (operative 
procedure with caution), 2013 (COPD guideline: 
valve not mentioned) 
England (NICE): 2013, RCT, not recommended  
Austria (LBI-HTA): 2010, RCT, not recommended 
USA 2008 (rejection,  
no authorization),  
RCT (2007) 
No coverage 
Canada No application No coverage (?) 
Australia No application MSAC: 2001, RCT, not recommended 
Paracor Ventricular 
Support System (PVSS) 
  
Europe 2000 (approval),  
no information 
Netherlands (CVZ): no assessment 
Germany (G-BA, IQWIG, MDS): no assessment 
England (NICE): no assessment 
Austria (LBI-HTA): no assessment 
USA 2000 (rejection,  
no authorization),  
no information 
No coverage 
Canada No application No coverage (?) 
Australia No application No coverage (?) 
Annular repair device  
Barricaid® 
  
Europe 2009 (approval),  
no information 
Netherlands (CVZ): no assessment 
Germany (G-BA, IQWIG, MDS): no assessment 
England (NICE): assessment in progress  
Austria (LBI-HTA): 2013, case series, not recommended 
USA No application No coverage (?) 
Canada No application No coverage (?) 
Australia 2011 (approval), CE marking No assessment, coverage (?) 
 
4 more were assessed  
in USA (but not 
generally approved) 
CE marking 2-5 years 
before other approvals 
 
with less mature  
clinical evidence 
Discussion 
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Medical Device 
Authorization:  
year, best available evidence 
Reimbursement:  
year, evidence, recommendation 
Rheofilter ER-4000   
Europe 1998 (approval),  
no information 
Netherlands (CVZ): 2010, SLR+ RCT,  
not recommended 
Germany (G-BA, IQWIG, MDS): 2000, RCT,  
not recommended 
England (NICE): 2010, only in research 
Austria (LBI-HTA): 2008, RCT, not recommended 
USA No application No coverage (?) 
Canada 2002-2005 (approval), 
withdrawal of authorization 
on RCT 
No coverage 
Australia No application No coverage (?) 
BSD-2000 Microwave 
Hyperthermia System 
  
Europe No information on year 
(approval), no information 
Netherlands (CVZ): 2011, RCT, coverage only cervix 
carcinoma, not recommended for other indications  
Germany (G-BA, IQWIG, MDS): 2005, RCT,  
not recommended 
England (NICE): 2007, RCT, only in research 
Austria (LBI-HTA): 2010-2012, RCT, not recommended 
USA Since 2011 (only under HDE, 
cervix carcinoma), RCT 
only in research 
Canada No application No coverage (?) 
Australia No application No coverage (?) 
Amplatzer™ PFO 
Occluder 
  
Europe No information on year 
(approval), no infor-mation 
Netherlands (CVZ): no assessment,  
Germany (G-BA, IQWIG, MDS): no assessment 
England (NICE): 2005 + 2011, not recommended  
Austria (LBI-HTA): no assessment 
USA Until 2006 (only under 
HDE), no authorization  
after 2006  
No coverage (?) 
Canada 2001 (approval),  
no information 
no assessment 
Australia 2006 (approval),  
no information 
MSAC: 2013 assessment, consultation ongoing 
MitraClip®   
Europe 2008 (approval),  
no information 
Netherlands (CVZ): no assessment  
Germany (G-BA, IQWIG, MDS): 2010+2012, RCT, 
not recommended  
England (NICE): 2009, case series, not recommended 
Austria (LBI-HTA): 2010+2012, RCT, not recommended 
USA 2013 (approval), RCT CMS: application for coverage in 2014 
Aetna: no information 
BCBS: no information 
Healthcare United: coverage, RCT 
Kaiser Permanente: coverage, no information 
AHRQ: high impact, RCT 
Canada No application No coverage (?) 
Australia 2010 (approval),  
no information 
MSAC: 2011, RCT, not recommended 
?  not known, ev. in DRGs included. 
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Yet, these major differences in the approval of devices support the assump-
tion of a rather easily accessible and low-evidence requirements system for 
authorization in the European Union [45]. Whereas other countries consider 
the devices as not safe and effective for the market, they may be legally mar-
keted in Europe. In addition, each of the other systems requires effectiveness 
data in combination with safety studies during the authorization assessment, 
except in Europe [47]. Consequently, devices may enter purely on the basis of 
safety.  
These results are in accordance with earlier findings, concluding that the 
access to new medical devices in Europe is faster with fewer regulatory re-
quirements for high-quality clinical evidence for authorization [16, 204].  
Further, it has been crucial for this research to access the evidence used for 
the authorization process in the four selected regions. However, it has been 
rather difficult to gather enough relevant data from the regulatory authorities 
in Europe, Australia and Canada, but not so in the USA.  
In Europe, with the many (168) decentralized Notified Bodies, all entitled to 
conduct a conformity assessment and grant the CE marking, no system of 
transparency is installed, neither for the assessment process nor for the results: 
There is no publicly available information or summary describing the basis 
for granting a CE marking. Members of the public, therefore, cannot find out 
information about the process (place of application, requirements for applica-
tion, pre-defined criteria for decisions) or the rationale for an approval (effica-
cy and safety data) [38]. Consequently, the public has no overview of which 
Notified Body has granted which CE marking, and what evidence has been 
used to reach this decision.  
In Australia and Canada, at least publicly accessible databases with infor-
mation whether the device in question has been approved are installed (as a 
minimum requirement), but the clinical evidence used for the approvals is also 
not public. The ARTG listing (Australia) and the TPD device license listing 
(Canada) can be scanned for information about approved devices. In both 
systems, every approved device can be found with the respective manufacturer. 
Nonetheless, evidence that has granted the decision for the approval of the 
device is not made available for the public. 
The FDA is the only regulatory body that has publicly available summaries 
of safety and effectiveness data for approved or rejected devices. The FDA has 
a public listing and an accessible database of all approved devices in place. 
Yet, the evidence gathered for the three devices (MitraClip, BSD-2000 and 
Zephyr) derived from committee panels. These committee panels were con-
ducted to discuss and review the premarket application of these devices. Gen-
erally, it is not the case that such a committee panel is held for every device, 
but rather only if the FDA urges experts for advice. 
 
Reimbursement  
The decision making on reimbursement within the four regions and the many 
countries is very diverse. In the European Union, healthcare has always been 
regarded as a matter of national sovereignty. Therefore, many (actually 28) 
different systems exist. In the USA, Canada and Australia, national insurance 
programs and advisory committees assess devices and give recommendations.  
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In order to facilitate this research, only four countries, namely The Nether-
lands, England, Germany and Austria and their (national) advising institutes 
have been selected for a more detailed analysis of health technology assess-
ments as support for reimbursement decisions. In the European Union, all 
seven medical devices have received CE marking. However, none of the seven 
medical devices was recommended for reimbursement. Some devices have not 
been assessed by all bodies, but the majority of those assessed were not sup-
ported for (general) reimbursement. Often the reason is that current evidence 
is not enough to ensure patient benefit and safety. Some devices are recom-
mended for “research only.” 
The evidence levels have ranged from very high – more than one randomized 
controlled trial – to rather low – uncontrolled case series. However, even after 
conducting several randomized controlled trials, reimbursement advising in-
stitutes looked at the safety and effectiveness in more detail, considering pa-
tient-relevant endpoints rather than surrogate endpoints alone.  
The MitraClip®, the only device authorized in the USA, has just very recently 
been approved and therefore some health insurance programs have not made 
decisions on the coverage of the device yet. An application for coverage has 
been submitted and a decision will be taken in 2014. Only Healthcare United 
has published a final decision paper stating that the MitraClip® will be in-
cluded in their medical benefit scheme.  
In Canada, no information about the one approved device (Amplatzer) was 
available. In Australia, all four devices – three of which had been assessed, 
were not recommended for reimbursement. It was decided that current evi-
dence is not enough for a positive recommendation.  
Since diagnostic-related groups (DRGs) are installed in many countries as flat 
rates for reimbursing medical interventions rather than separate reimburse-
ment of devices, one cannot conclude that – even after negative recommen-
dations – the devices are not in use or not covered. 
 
Evidence requirements in authorization and reimbursement 
In this research, it was observed that in Europe the seven medical devices 
analyzed have received CE marking and passed the gateway of authorization 
easily, but were then not recommended for reimbursement because of a lack 
of good quality clinical evidence and relevant outcomes. This can be explained 
with the very low evidence requirements for the European pre-market author-
ization and higher requirements for proofs of clinical benefit in national de-
cision-support assessments for reimbursement. The same seems to apply in 
Australia.  
In the USA, the FDA applies much stricter evidence requirements for mar-
ket authorization. Consequently, it might seem in line that devices that were 
authorized by the FDA are as well positively recommended by the health in-
surance programs. But this research generated too little evidence for such a 
broad conclusion or hypothesis. 
In Canada, it is difficult to make observations, as no information was available 
for the reimbursement assessments of the approved device.  
The following figures try to summarize the information on years of approval 
and development of evidence over the years before and after approval. Only 
the highest level of evidence available before and after approval of the device 
is presented.  
level of evidence 
ranging from  
RCTs to case series 
none of the 7 devices 
recommended for 
reimbursement in 
Europe 
patient-relevant 
outcomes demanded 
USA – MitraClip® 
reimbursement by 
Healthcare United  
Canada: no information 
Australia: none of the  
4 devices recommended 
for reimbursement  
within DRGs the devices 
are possibly covered  
Europe and Australia  
– low evidence for 
authorization vs. strict 
reimbursement 
assessment  
USA – FDA starts with 
strict assessments 
Canada no information  
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Table 6-2: Timeline for time of approval(s) and evidence development over the years 
Timeline Device name 
 
     2007 – VENT design         2010 – VENT reporting    2012 – VENT Europe 
 
 2003 – CE marking                    2011 – ARTG inclusion 
2008 - PMA rejection FDA 
 
 
Zephyr®  
Endobronchial 
Valve 
 
                                   2007– Case series       2012 – RCT – Rational and design  
 
     2000 – CE marking 
2000 – PMA rejection FDA  
 
 
Paracor  
Ventricular 
Support System 
(PVSS) 
 
2006 – Prospective, multicenter controlled clinical study 
                2009 – Benchtop    2011 – Technical feasibility study 
                       2012 – Non-randomized, partly uncontrolled study 
 
           2009 – CE marking  2011 – ARTG inclusion 
 
 
annular  
repair device  
Barricaid® 
 
                                                 2003 – SLR    2005 – SLR          2009 – SLR  
                                                        
 
1998 – CE marking              2002-2005 – Device License 
 
 
Rheofilter  
ER-4000 
    1996 – RCT  
 
 ? – CE marking     2011 – FDA approval under HDE 
 
BSD-2000  
Microwave  
Hyperthermia 
System 
 
  2005/2006 – RCT    2007/2008 – 3 RCTs          2011 – RCT     2012 – RCT     2013 – SLR  
   
                 2006 – ARTG inclusion 
       2001 – Device License  
? – CE marking 
 
Amplatzer™ 
PFO  
Occluder 
 
 2005 – RCT                  2011 – RCT         2013 – RCT  2013 – SLR  
 
2008 – CE marking   2011 – ARTG inclusion  2013 – PMA approval 
MitraClip® 
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7 Conclusion 
It can be mainly concluded that it is strongly recommended that the European 
authorization (premarket approval) system will need to undergo a change to-
wards transparency in the approval processes and underlying evidence of an 
authorization result (as access to the market). The requirements outlined in 
the Open Letter of a number of experts to the EU Commission [38] that Eu-
rope needs a “central, transparent, and evidence-based regulation process” 
holds true especially for high-risk devices when looking at the results of this 
research. Mutual learning and knowledge exchange monitoring the other au-
thorization systems would enhance improvement.  
In addition, several countries have started “conditional coverage” or “coverage 
under evidence development” programs in order to give “promising” devices 
with immature or only partly convincing clinical data a chance to prove their 
promises. These programs should be closely monitored, analyzed and assessed. 
Moreover, an “early dialogue” between national HTA agencies, reimburse-
ment institutions, regulators and device manufacturers on required clinical 
evidence and patient-relevant endpoints could be taken into consideration. 
EUnetHTA/European Network for HTA will possibly play an important role 
in the field of activities. 
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requirements 
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Appendix 2: PRISMA Tree for reimbursement part  
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